RAS Proteins and Their Regulators in Human Disease

Cell

170, 17-33

DOI: 10.1016/j.cell.2017.06.009

Citation Report

#	Article	IF	Citations
1	Optic pathway gliomas in neurofibromatosis-1: Controversies and recommendations. Annals of Neurology, 2007, 61, 189-198.	2.8	531
2	A doubleâ€edged sword: The world according to Capicua in cancer. Cancer Science, 2017, 108, 2319-2325.	1.7	24
3	Immunohistochemical evalulation of activated Ras and Rac1 as potential downstream effectors of aquaporin-5 in breast cancer inÂvivo. Biochemical and Biophysical Research Communications, 2017, 493, 1210-1216.	1.0	23
4	KRAS Alleles: The Devil Is in the Detail. Trends in Cancer, 2017, 3, 686-697.	3.8	257
5	Natural Compounds in Cancer Prevention: Effects of Coffee Extracts and Their Main Polyphenolic Component, 5â€Oâ€Caffeoylquinic Acid, on Oncogenic Ras Proteins. Chemistry - an Asian Journal, 2017, 12, 2457-2466.	1.7	46
6	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes. British Journal of Pharmacology, 2017, 174, S272-S359.	2.7	597
7	AP-1 Transcription Factors and the BAF Complex Mediate Signal-Dependent Enhancer Selection. Molecular Cell, 2017, 68, 1067-1082.e12.	4.5	328
8	Combating NRAS mutant melanoma: from bench to bedside. Melanoma Management, 2017, 4, 183-186.	0.1	8
9	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. Frontiers in Immunology, 2017, 8, 1597.	2.2	225
10	Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer. Frontiers in Immunology, 2017, 8, 1412.	2.2	80
11	Intersectin-1s deficiency in pulmonary pathogenesis. Respiratory Research, 2017, 18, 168.	1.4	5
12	Nanodiscs: A Controlled Bilayer Surface for the Study of Membrane Proteins. Annual Review of Biophysics, 2018, 47, 107-124.	4.5	68
13	Germline control of somatic Kras mutations in mouse lung tumors. Molecular Carcinogenesis, 2018, 57, 745-751.	1.3	3
14	Early onset sporadic colorectal cancer: Worrisome trends and oncogenic features. Digestive and Liver Disease, 2018, 50, 521-532.	0.4	65
15	Emerging therapeutic targets for neurofibromatosis type 1. Expert Opinion on Therapeutic Targets, 2018, 22, 419-437.	1.5	53
16	Evaluation of 4â€bp insertion/deletion polymorphism within the 3â€²UTR of SGSM3 in bladder cancer using mismatch PCRâ€RFLP method: A preliminary report. Journal of Cellular Biochemistry, 2018, 119, 6566-6574.	1.2	5
17	It Takes Two To Target: A Study in KRAS Dimerization. Biochemistry, 2018, 57, 2289-2290.	1.2	5
18	Structural characterization of 14-3-3Î¶ in complex with the human Son of sevenless homolog 1 (SOS1). Journal of Structural Biology, 2018, 202, 210-215.	1.3	16

#	Article	IF	Citations
19	Structural fingerprints, interactions, and signaling networks of RAS family proteins beyond RAS isoforms. Critical Reviews in Biochemistry and Molecular Biology, 2018, 53, 130-156.	2.3	34
20	Isoform-selective activity-based profiling of ERK signaling. Chemical Science, 2018, 9, 2419-2431.	3.7	34
21	A â€œTug of Warâ€•Maintains a Dynamic Proteinâ€“Membrane Complex: Molecular Dynamics Simulations of C-Raf RBD-CRD Bound to K-Ras4B at an Anionic Membrane. ACS Central Science, 2018, 4, 298-305.	5.3	54
22	Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. Gut, 2018, 67, 1328-1341.	6.1	77
23	KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. Cell, 2018, 172, 857-868.e15.	13.5	220
24	Mechanistic regulation of epithelial-to-mesenchymal transition through RAS signaling pathway and therapeutic implications in human cancer. Journal of Cell Communication and Signaling, 2018, 12, 513-527.	1.8	36
25	Somatic Activating KRAS Mutations in Arteriovenous Malformations of the Brain. New England Journal of Medicine, 2018, 378, 250-261.	13.9	330
26	Unraveling the human protein atlas of metastatic melanoma in the course of ultraviolet radiation-derived photo-therapy. Journal of Proteomics, 2018, 188, 119-138.	1.2	4
27	Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimerâ€™s disease. Critical Reviews in Biochemistry and Molecular Biology, 2018, 53, 279-310.	2.3	95
28	Ras and Rap Signal Bidirectional Synaptic Plasticity via Distinct Subcellular Microdomains. Neuron, 2018, 98, 783-800.e4.	3.8	68
29	Molecular characterization and pathogenesis of gastrointestinal stromal tumor. Translational Gastroenterology and Hepatology, 2018, 3, 2-2.	1.5	34
30	A model for RAS mutation patterns in cancers: finding the sweet spot. Nature Reviews Cancer, 2018, 18, 767-777.	12.8	266
31	Tonic ATP-mediated growth suppression in peripheral nerve glia requires arrestin-PP2 and is evaded in NF1. Acta Neuropathologica Communications, 2018, 6, 127.	2.4	9
32	A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab. Experimental and Molecular Medicine, 2018, 50, 1-12.	3.2	20
33	Integrating chemical and mechanical signals through dynamic coupling between cellular protrusions and pulsed ERK activation. Nature Communications, 2018, 9, 4673.	5.8	48
34	LZTR1 is a regulator of RAS ubiquitination and signaling. Science, 2018, 362, 1171-1177.	6.0	142
35	Cancer cells exploit an orphan RNA to drive metastatic progression. Nature Medicine, 2018, 24, 1743-1751.	15.2	26
36	MYC and RAS are unable to cooperate in overcoming cellular senescence and apoptosis in normal human fibroblasts. Cell Cycle, 2018, 17, 2697-2715.	1.3	13

#	Article	IF	Citations
37	Statins Reduce Thoracic Aortic Aneurysm Growth in Marfan Syndrome Mice via Inhibition of the Rasâ€Induced ERK (Extracellular Signalâ€Regulated Kinase) Signaling Pathway. Journal of the American Heart Association, 2018, 7, e008543.	1.6	28
38	UBIAD1 suppresses the proliferation of bladder carcinoma cells by regulating H-Ras intracellular trafficking via interaction with the C-terminal domain of H-Ras. Cell Death and Disease, 2018, 9, 1170.	2.7	12
39	De novo mutations in the GTP/GDP-binding region of RALA, a RAS-like small GTPase, cause intellectual disability and developmental delay. PLoS Genetics, 2018, 14, e1007671.	1.5	16
40	Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC. Frontiers in Oncology, 2018, 8, 532.	1.3	27
41	RAS variant signalling. Biochemical Society Transactions, 2018, 46, 1325-1332.	1.6	61
42	Metabolic Plasticity of Tumor Cell Mitochondria. Frontiers in Oncology, 2018, 8, 333.	1.3	74
43	Therapeutic strategies to target RAS-mutant cancers. Nature Reviews Clinical Oncology, 2018, 15, 709-720.	12.5	274
44	Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Nonâ€Small Cell Lung Cancer. Cancer Discovery, 2018, 8, 1598-1613.	7.7	71
45	SHOC2â€MRASâ€PP1 complex positively regulates RAF activity and contributes to Noonan syndrome pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10576-E10585.	3.3	59
46	Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes. JCI Insight, 2018, 3, .	2.3	71
47	Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma. Experimental Hematology and Oncology, 2018, 7, 21.	2.0	40
48	The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway. Endocrine Reviews, 2018, 39, 676-700.	8.9	157
49	Assessment of mutation probabilities of KRAS G12 missense mutants and their long-timescale dynamics by atomistic molecular simulations and Markov state modeling. PLoS Computational Biology, 2018, 14, e1006458.	1.5	59
50	NF-ÎºB, Mesenchymal Differentiation and Glioblastoma. Cells, 2018, 7, 125.	1.8	44
51	Chemoproteomic Discovery of a Ritanserin-Targeted Kinase Network Mediating Apoptotic Cell Death of Lung Tumor Cells. Molecular Pharmacology, 2018, 94, 1246-1255.	1.0	11
52	Recent Advances in the Diagnosis and Pathogenesis of Neurofibromatosis Type 1 (NF1)-associated Peripheral Nervous System Neoplasms. Advances in Anatomic Pathology, 2018, 25, 353-368.	2.4	34
53	Study of Ras/<scp>MAPK</scp> pathway gene variants in Chilean patients with Cryptorchidism. Andrology, 2018, 6, 579-584.	1.9	2
54	Modelling Cooperative Tumorigenesis inDrosophila. BioMed Research International, 2018, 2018, 1-29.	0.9	33

#	Article	IF	Citations
55	Principles of Targeted Therapy. , 2018, , 1-15.		0
56	A natural killerâ€“dendritic cell axis defines checkpoint therapyâ€“responsive tumor microenvironments. Nature Medicine, 2018, 24, 1178-1191.	15.2	679
57	Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer. Clinical Cancer Research, 2018, 24, 4854-4864.	3.2	49
58	Translation deregulation in human disease. Nature Reviews Molecular Cell Biology, 2018, 19, 791-807.	16.1	161
59	Tumor promoter TPA activates Wnt/Î²-catenin signaling in a casein kinase 1-dependent manner. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7522-E7531.	3.3	27
60	Network-Based Predictors of Progression in Head and Neck Squamous Cell Carcinoma. Frontiers in Genetics, 2018, 9, 183.	1.1	34
61	RAS GTPase-dependent pathways in developmental diseases: old guys, new lads, and current challenges. Current Opinion in Cell Biology, 2018, 55, 42-51.	2.6	18
62	Reactive Oxygen Species and Mitochondrial Dynamics: The Yin and Yang of Mitochondrial Dysfunction and Cancer Progression. Antioxidants, 2018, 7, 13.	2.2	325
63	A New Strategy to Control and Eradicate â€œUndruggableâ€•Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. Cancers, 2018, 10, 142.	1.7	17
64	Novel Mutations in RASGRP1 are Associated with Immunodeficiency, Immune Dysregulation, and EBV-Induced Lymphoma. Journal of Clinical Immunology, 2018, 38, 699-710.	2.0	37
65	RAS signalling in energy metabolism and rare human diseases. Biochimica Et Biophysica Acta - Bioenergetics, 2018, 1859, 845-867.	0.5	47
66	Activation of Rho Family GTPases by Small Molecules. ACS Chemical Biology, 2018, 13, 1514-1524.	1.6	13
67	Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Pharmacological Research, 2018, 135, 239-258.	3.1	154
68	Phosphorylation promotes binding affinity of Rap-Raf complex by allosteric modulation of switch loop dynamics. Scientific Reports, 2018, 8, 12976.	1.6	10
69	Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment. Nature Communications, 2018, 9, 3169.	5.8	100
70	Gliding Basal Cell Migration of the Urothelium during Wound Healing. American Journal of Pathology, 2018, 188, 2564-2573.	1.9	10
71	Loss of RapC causes defects in cytokinesis, cell migration, and multicellular development of Dictyostelium. Biochemical and Biophysical Research Communications, 2018, 499, 783-789.	1.0	7
72	Synthesis of Ras proteins and their application in biofunctional studies. Chinese Chemical Letters, 2018, 29, 1043-1050.	4.8	8

#	Article	IF	Citations
73	The tumor suppressor protein p53 and the ferroptosis network. Free Radical Biology and Medicine, 2019, 133, 162-168.	1.3	384
74	Some chinks in RAS armor. Seminars in Cancer Biology, 2019, 54, iii-iv.	4.3	0
75	Ras-Specific GTPase-Activating Proteinsâ€"Structures, Mechanisms, and Interactions. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a031500.	2.9	40
76	Concepts toward directing human astroplasticity to promote neuroregeneration. Developmental Dynamics, 2019, 248, 21-33.	0.8	3
77	Saccharomyces cerevisiae Ras2 restores filamentation but cannot activate the first step of GPI anchor biosynthesis in Candida albicans. Biochemical and Biophysical Research Communications, 2019, 517, 755-761.	1.0	2
78	Principles of Targeted Therapy. , 2019, , 165-179.		0
79	Conserved NDR/LATS kinase controls RAS GTPase activity to regulate cell growth and chronological lifespan. Molecular Biology of the Cell, 2019, 30, 2598-2616.	0.9	14
80	Identification of lysine methylation in the core GTPase domain by GoMADScan. PLoS ONE, 2019, 14, e0219436.	1.1	6
81	Role of KRAS in regulating normal human airway basal cell differentiation. Respiratory Research, 2019, 20, 181.	1.4	5
83	Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. Nature Communications, 2019, 10, 3722.	5.8	131
84	Mutant-Specific Targeting of Ras G12C Activity by Covalently Reacting Small Molecules. Cell Chemical Biology, 2019, 26, 1338-1348.	2.5	12
85	RAS in pancreatic cancer. Biochemical Society Transactions, 2019, 47, 961-972.	1.6	51
86	The NF2 tumor suppressor merlin interacts with Ras and RasGAP, which may modulate Ras signaling. Oncogene, 2019, 38, 6370-6381.	2.6	36
87	Investigation of GTP-dependent dimerization of G12X K-Ras variants using ultraviolet photodissociation mass spectrometry. Chemical Science, 2019, 10, 8025-8034.	3.7	21
88	Deactivation Pathway of Ras GTPase Underlies Conformational Substates as Targets for Drug Design. ACS Catalysis, 2019, 9, 7188-7196.	5.5	77
89	Longevity: Lesson from Model Organisms. Genes, 2019, 10, 518.	1.0	66
90	Fitness of unregulated human Ras mutants modeled by implementing computational mutagenesis and machine learning techniques. Heliyon, 2019, 5, e01884.	1.4	3
91	Structures of N-terminally processed KRAS provide insight into the role of N-acetylation. Scientific Reports, 2019, 9, 10512.	1.6	47

#	Article	IF	Citations
92	RAS-Responsive Element-Binding Protein 1 Blocks the Granulocytic Differentiation of Myeloid Leukemia Cells. Oncology Research, 2019, 27, 809-818.	0.6	7
93	PEG-Derivatized Dual-Functional Nanomicelles for Improved Cancer Therapy. Frontiers in Pharmacology, 2019, 10, 808.	1.6	33
94	PIP2 Influences the Conformational Dynamics of Membrane-Bound KRAS4b. Biochemistry, 2019, 58, 3537-3545.	1.2	30
95	Endogenous IQGAP1 and IQGAP3 do not functionally interact with Ras. Scientific Reports, 2019, 9, 11057.	1.6	12
96	RAS mutations in human cancers: Roles in precision medicine. Seminars in Cancer Biology, 2019, 59, 23-35.	4.3	85
97	KRASG12C inhibitors on the horizon. Future Medicinal Chemistry, 2019, 11, 923-925.	1.1	7
98	PKCÎµ-dependent H-Ras activation encompasses the recruitment of the RasGEF SOS1 and of the RasGAP neurofibromin in the lipid rafts of embryonic neurons. Neurochemistry International, 2019, 131, 104582.	1.9	4
99	KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22122-22131.	3.3	85
100	The Ras switch in structural and historical perspective. Biological Chemistry, 2019, 401, 143-163.	1.2	51
101	Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling. Molecular Cell, 2019, 76, 872-884.e5.	4.5	76
102	Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRASâ€“Dependent Pancreatic Ductal Adenocarcinoma. Cancer Research, 2019, 79, 5612-5625.	0.4	11
103	The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature, 2019, 575, 217-223.	13.7	1,375
104	Pancreatic Ductal Adenocarcinoma: MicroRNAs Affecting Tumor Growth and Metastasis in Preclinical In Vivo Models. Cancer Genomics and Proteomics, 2019, 16, 451-464.	1.0	17
105	Rational Design and Synthesis of Diverse Pyrimidine Molecules Bearing Sulfonamide Moiety as Novel ERK Inhibitors. International Journal of Molecular Sciences, 2019, 20, 5592.	1.8	10
106	CD146 Regulates Growth Factor-Induced mTORC2 Activity Independent of the PI3K and mTORC1 Pathways. Cell Reports, 2019, 29, 1311-1322.e5.	2.9	16
107	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology, 2019, 176, S297-S396.	2.7	423
108	Concomitant deletion of HRAS and NRAS leads to pulmonary immaturity, respiratory failure and neonatal death in mice. Cell Death and Disease, 2019, 10, 838.	2.7	9
109	AI Meets Exascale Computing: Advancing Cancer Research With Large-Scale High Performance Computing. Frontiers in Oncology, 2019, 9, 984.	1.3	23

#	Article	IF	Citations
110	IL-1Î² and Statin Treatment in Patients with Myocardial Infarction and Diabetic Cardiomyopathy. Journal of Clinical Medicine, 2019, 8, 1764.	1.0	21
111	Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia. Expert Review of Anticancer Therapy, 2019, 19, 717-729.	1.1	12
112	Liraglutide suppresses the metastasis of PANC-1 co-cultured with pancreatic stellate cells through modulating intracellular calcium content. Endocrine Journal, 2019, 66, 1053-1062.	0.7	5
113	A pooled single-cell genetic screen identifies regulatory checkpoints in the continuum of the epithelial-to-mesenchymal transition. Nature Genetics, 2019, 51, 1389-1398.	9.4	150
114	Lycopene Inhibits Activation of Epidermal Growth Factor Receptor and Expression of Cyclooxygenase-2 in Gastric Cancer Cells. Nutrients, 2019, 11, 2113.	1.7	32
115	Robust and automated detection of subcellular morphological motifs in 3D microscopy images. Nature Methods, 2019, 16, 1037-1044.	9.0	68
116	Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis . International Journal of Nanomedicine, 2019, Volume 14, 6589-6600.	3.3	23
117	In vivo activation of PEGylated long circulating lipid nanoparticle to achieve efficient siRNA delivery and target gene knock down in solid tumors. Journal of Controlled Release, 2019, 311-312, 245-256.	4.8	28
118	The relevance between the immune response-related gene module and clinical traits in head and neck squamous cell carcinoma . Cancer Management and Research, 2019, Volume 11, 7455-7472.	0.9	37
119	Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. Science Translational Medicine, 2019, 11, .	5.8	150
120	Proteogenomic Network Analysis of Context-Specific KRAS Signaling in Mouse-to-Human Cross-Species Translation. Cell Systems, 2019, 9, 258-270.e6.	2.9	44
121	USP11 promotes growth and metastasis of colorectal cancer via PPP1CA-mediated activation of ERK/MAPK signaling pathway. EBioMedicine, 2019, 48, 236-247.	2.7	84
122	Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. Cell Reports, 2019, 29, 118-134.e8.	2.9	63
123	New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness. Frontiers in Oncology, 2019, 9, 953.	1.3	97
124	Regulation of Selective Proteolysis in Cancer. , 2019, , .		0
125	Pathogenic Epigenetic Consequences of Genetic Alterations in IDH-Wild-Type Diffuse Astrocytic Gliomas. Cancer Research, 2019, 79, 4814-4827.	0.4	6
126	TRPML1 and RAS-driven cancers â€“ exploring a link with great therapeutic potential. Channels, 2019, 13, 374-381.	1.5	16
127	Structural Perturbations due to Mutation (H1047R) in Phosphoinositide-3-kinase (PI3KÎ±) and Its Involvement in Oncogenesis: An in Silico Insight. ACS Omega, 2019, 4, 15815-15823.	1.6	21

#	Article	IF	Citations
128	Systemic MEK inhibition enhances the efficacy of 5-aminolevulinic acid-photodynamic therapy. British Journal of Cancer, 2019, 121, 758-767.	2.9	16
129	Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2545-2550.	3.3	96
130	Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RASâ€“SOS1 interaction. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2551-2560.	3.3	262
131	Oncogenic KRAS hotspot mutations are rare in IDHâ€mutant gliomas. Brain Pathology, 2019, 29, 321-324.	2.1	4
132	Comprehensive molecular and clinicopathological analysis of vascular malformations: A study of 319 cases. Genes Chromosomes and Cancer, 2019, 58, 541-550.	1.5	50
133	Progress in targeting RAS with small molecule drugs. Biochemical Journal, 2019, 476, 365-374.	1.7	53
134	More than 18,000 effectors in the Legionella genus genome provide multiple, independent combinations for replication in human cells. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2265-2273.	3.3	164
135	Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors. Gene Therapy, 2019, 26, 277-286.	2.3	21
136	Localization of RalB signaling at endomembrane compartments and its modulation by autophagy. Scientific Reports, 2019, 9, 8910.	1.6	4
137	Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors. Clinical Cancer Research, 2019, 25, 5984-5996.	3.2	46
138	A germline mutation in Rab43 gene identified from a cancer family predisposes to a hereditary liver-colon cancer syndrome. BMC Cancer, 2019, 19, 613.	1.1	4
139	SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 13330-13339.	3.3	33
140	The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 1046-1060.	0.5	52
141	The Ras Superfamily of Small GTPases in Non-neoplastic Cerebral Diseases. Frontiers in Molecular Neuroscience, 2019, 12, 121.	1.4	61
142	AKT and ERK dual inhibitors: The way forward?. Cancer Letters, 2019, 459, 30-40.	3.2	144
143	KRAS ^{G12C} inhibition produces a driver-limited state revealing collateral dependencies. Science Signaling, 2019, 12, .	1.6	123
144	Dissociation of the Signaling Protein Kâ€Ras4B from Lipid Membranes Induced by a Molecular Tweezer. Chemistry - A European Journal, 2019, 25, 9827-9833.	1.7	5
145	iTRAQ-Based Protein Profiling in CUMS Rats Provides Insights into Hippocampal Ribosome Lesion and Ras Protein Changes Underlying Synaptic Plasticity in Depression. Neural Plasticity, 2019, 2019, 1-15.	1.0	8

#	Article	IF	Citations
146	Time-resolved protein activation by proximal decaging in living systems. Nature, 2019, 569, 509-513.	13.7	146
147	SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors. Molecular Cancer Therapeutics, 2019, 18, 1323-1334.	1.9	60
148	Regulation of TORC2 function and localization by Rab5 GTPases in Saccharomyces cerevisiae. Cell Cycle, 2019, 18, 1084-1094.	1.3	6
149	Non-cytotoxic systemic treatment in malignant peripheral nerve sheath tumors (MPNST): A systematic review from bench to bedside. Critical Reviews in Oncology/Hematology, 2019, 138, 223-232.	2.0	22
150	Clinical and functional characterization of a novel RASopathyâ€causingSHOC2mutation associated with prenatalâ€onset hypertrophic cardiomyopathy. Human Mutation, 2019, 40, 1046-1056.	1.1	18
151	Comparison of PANAMutyper and PNAClamp for Detecting KRAS Mutations from Patients With Malignant Pleural Effusion. In Vivo, 2019, 33, 945-954.	0.6	1
153	Akt-ing Up Just About Everywhere: Compartment-Specific Akt Activation and Function in Receptor Tyrosine Kinase Signaling. Frontiers in Cell and Developmental Biology, 2019, 7, 70.	1.8	97
154	Activating KRAS mutations in arteriovenous malformations of the brain: frequency and clinicopathologic correlation. Human Pathology, 2019, 89, 33-39.	1.1	45
155	A YWHAZ Variant Associated With Cardiofaciocutaneous Syndrome Activates the RAF-ERK Pathway. Frontiers in Physiology, 2019, 10, 388.	1.3	23
156	Dampening oncogenic RAS signaling. Science, 2019, 363, 1280-1281.	6.0	25
157	New insights into germ cell tumor genomics. Andrology, 2019, 7, 507-515.	1.9	23
158	Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer. Journal of Personalized Medicine, 2019, 9, 15.	1.1	21
159	Both knock-down and overexpression of Rap2a small GTPase in macrophages result in impairment of NF-Î°B activity and inflammatory gene expression. Molecular Immunology, 2019, 109, 27-37.	1.0	9
160	Epidermal growth factor receptor controls glycogen phosphorylase in T cells through small GTPases of the RAS family. Journal of Biological Chemistry, 2019, 294, 4345-4358.	1.6	12
161	RIT1 oncoproteins escape LZTR1-mediated proteolysis. Science, 2019, 363, 1226-1230.	6.0	66
162	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. Leukemia, 2019, 33, 2111-2115.	3.3	21
163	High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions. Cell Reports, 2019, 27, 631-647.e5.	2.9	9
164	Targeting the ERK Signaling Pathway in Melanoma. International Journal of Molecular Sciences, 2019, 20, 1483.	1.8	116

#	Article	IF	Citations
165	Involvement of H-Ras in the adaptive immunity of Nile tilapia by regulating lymphocyte activation. Fish and Shellfish Immunology, 2019, 89, 281-289.	1.6	7
166	Targeting ERK1/2 protein-serine/threonine kinases in human cancers. Pharmacological Research, 2019, 142, 151-168.	3.1	202
167	Targeting Alterations in the RAFâ€“MEK Pathway. Cancer Discovery, 2019, 9, 329-341.	7.7	282
168	HRASâ€driven cancer cells are vulnerable to TRPML1 inhibition. EMBO Reports, 2019, 20, .	2.0	59
169	Blockade of RAF and autophagy is the one-two punch to take out Ras. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3965-3967.	3.3	5
170	3DBIONOTES v3.0: crossing molecular and structural biology data with genomic variations. Bioinformatics, 2019, 35, 3512-3513.	1.8	9
171	Introductory Chapter: Interactions between Environmental Chemicals and KRAS Oncogene in Different Cancers - Special Focus on Colorectal, Pancreatic, and Lung Cancers. , 2019, , .		0
172	The excitable signal transduction networks: movers and shapers of eukaryotic cell migration. International Journal of Developmental Biology, 2019, 63, 407-416.	0.3	39
173	Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma. Blood Advances, 2019, 3, 3214-3227.	2.5	19
174	A predation assay using amoebae to screen for virulence factors unearthed the first W. chondrophila inclusion membrane protein. Scientific Reports, 2019, 9, 19485.	1.6	4
175	Development of split luciferase complementation probes sensing KRAS/effector interaction. Translational and Regulatory Sciences, 2019, 1, 40-45.	0.2	0
176	Architecture of autoinhibited and active BRAFâ€“MEK1â€“14-3-3 complexes. Nature, 2019, 575, 545-550.	13.7	197
177	Bag-1 stimulates Bad phosphorylation through activation of Akt and Raf kinases to mediate cell survival in breast cancer. BMC Cancer, 2019, 19, 1254.	1.1	20
178	Partners in Crime: Clandestine Operations among RAS-RAF Accomplices in Promoting Tumorigenesis. Molecular Cell, 2019, 76, 853-855.	4.5	1
179	Endogenous Gastrin Collaborates With Mutant KRAS in Pancreatic Carcinogenesis. Pancreas, 2019, 48, 894-903.	0.5	8
180	Neutrophils in tPA-induced hemorrhagic transformations: Main culprit, accomplice or innocent bystander?. , 2019, 194, 73-83.		13
181	Roles of DNA repair enzyme OGG1 in innate immunity and its significance for lung cancer. , 2019, 194, 59-72.		45
182	Fragment-based drug discovery of triazole inhibitors to block PDEÎ´-RAS protein-protein interaction. European Journal of Medicinal Chemistry, 2019, 163, 597-609.	2.6	20

#	Article	IF	Citations
183	High prevalence of KRAS/BRAF somatic mutations in brain and spinal cord arteriovenous malformations. Brain, 2019, 142, 23-34.	3.7	107
184	Impact of RAS mutation subtype on clinical outcomeâ€"a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer. Oncogene, 2019, 38, 2953-2966.	2.6	38
185	Targeting the Î±4â€“Î±5 dimerization interface of K-RAS inhibits tumor formation in vivo. Oncogene, 2019, 38, 2984-2993.	2.6	49
186	HGF-induced migration depends on the PI(3,4,5)P3-binding microexon-spliced variant of the Arf6 exchange factor cytohesin-1. Journal of Cell Biology, 2019, 218, 285-298.	2.3	37
187	RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. Journal of Clinical Pathology, 2019, 72, 135-139.	1.0	28
188	Dual Targeting of EGFR and IGF1R in the TNFAIP8 Knockdown Nonâ€“Small Cell Lung Cancer Cells. Molecular Cancer Research, 2019, 17, 1207-1219.	1.5	15
189	Mechanisms of Resistance to Immune Checkpoint Blockade. American Journal of Clinical Dermatology, 2019, 20, 41-54.	3.3	83
190	Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development. Leukemia, 2019, 33, 957-968.	3.3	22
191	RAS-mediated oncogenic signaling pathways in human malignancies. Seminars in Cancer Biology, 2019, 54, 1-13.	4.3	115
192	Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1. Journal of Neuroscience Research, 2019, 97, 45-56.	1.3	15
193	â€œExamining RAS pathway rewiring with a chemically inducible activator of RASâ€• Small GTPases, 2020, 11, 413-420.	0.7	5
194	Ribosome profiling analysis identified a KRAS-interacting microprotein that represses oncogenic signaling in hepatocellular carcinoma cells. Science China Life Sciences, 2020, 63, 529-542.	2.3	36
195	Intraoperative Flurbiprofen Treatment Alters Immune Checkpoint Expression in Patients Undergoing Elective Thoracoscopic Resection of Lung Cancer. Medical Principles and Practice, 2020, 29, 150-159.	1.1	7
196	Rce1 suppresses invasion and metastasis of hepatocellular carcinoma via epithelialâ€“mesenchymal transition induced by the TGFâ€Î²1/Hâ€Ras signaling pathway. Journal of Cellular Physiology, 2020, 235, 2506-2520.	2.0	7
197	The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discovery, 2020, 10, 54-71.	7.7	820
198	NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation. Acta Neuropathologica, 2020, 139, 157-174.	3.9	13
199	Therapeutic targeting of RAS: New hope for drugging the â€œundruggableâ€• Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118570.	1.9	77
200	H-Ras activation and fibroblast-induced TGF-Î² signaling promote laminin-332 accumulation and invasion in cutaneous squamous cell carcinoma. Matrix Biology, 2020, 87, 26-47.	1.5	23

#	Article	IF	Citations
201	Inhibition of K-Ras4B-plasma membrane association with a membrane microdomain-targeting peptide. Chemical Science, 2020, 11, 826-832.	3.7	6
202	Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature, 2020, 577, 421-425.	13.7	321
203	Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. Autophagy, 2020, 16, 2069-2083.	4.3	319
204	PersonalizingKRAS-Mutant Alleleâ€“Specific Therapies. Cancer Discovery, 2020, 10, 23-25.	7.7	6
205	Ras isoforms: signaling specificities in CD40 pathway. Cell Communication and Signaling, 2020, 18, 3.	2.7	14
206	Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. Seminars in Cancer Biology, 2020, 65, 51-64.	4.3	63
207	Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nature Medicine, 2020, 26, 39-46.	15.2	236
208	The effects of statins with a high hepatoselectivity rank on the extra-hepatic tissues; New functions for statins. Pharmacological Research, 2020, 152, 104621.	3.1	5
209	The current understanding of KRAS protein structure and dynamics. Computational and Structural Biotechnology Journal, 2020, 18, 189-198.	1.9	142
210	Proliferative signaling by ERBB proteins and RAF/MEK/ERK effectors in polycystic kidney disease. Cellular Signalling, 2020, 67, 109497.	1.7	21
211	High-throughput phenotyping reveals expansive genetic and structural underpinnings of immune variation. Nature Immunology, 2020, 21, 86-100.	7.0	32
212	An intrinsic role of IL-33 in Treg cellâ€“mediated tumor immunoevasion. Nature Immunology, 2020, 21, 75-85.	7.0	82
213	Targeting Mutant KRAS for Immunogenic Cell Death Induction. Trends in Pharmacological Sciences, 2020, 41, 1-3.	4.0	3
214	Oncogenic pathways and the electron transport chain: a dangeROS liaison. British Journal of Cancer, 2020, 122, 168-181.	2.9	99
215	After Nf1 loss in Schwann cells, inflammation drives neurofibroma formation. Neuro-Oncology Advances, 2020, 2, i23-i32.	0.4	15
216	A chemically-controlled system for activating RAS GTPases. Methods in Enzymology, 2020, 633, 103-117.	0.4	0
217	Addressing cancer signal transduction pathways with antisense and siRNA oligonucleotides. NAR Cancer, 2020, 2, zcaa025.	1.6	16
218	DEPDC1 upâ€regulates RAS expression to inhibit autophagy in lung adenocarcinoma cells. Journal of Cellular and Molecular Medicine, 2020, 24, 13303-13313.	1.6	13

#	Article	IF	Citations
219	Design, synthesis and biological evaluation of novel 1,3,4-thiadiazole derivatives as anti-glioblastoma agents targeting the AKT pathway. Bioorganic Chemistry, 2020, 105, 104362.	2.0	7
220	Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells. Cancer Letters, 2020, 495, 135-144.	3.2	8
221	Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients. Cell, 2020, 183, 850-859.	13.5	128
222	Ras, PI3K and mTORC2 â€“ three's a crowd?. Journal of Cell Science, 2020, 133, .	1.2	22
223	SOS GEFs in health and disease. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188445.	3.3	44
224	Hydrostatic pressure promotes endothelial tube formation through aquaporin 1 and Ras-ERK signaling. Communications Biology, 2020, 3, 152.	2.0	24
225	Salmonella-based platform for efficient delivery of functional binding proteins to the cytosol. Communications Biology, 2020, 3, 342.	2.0	14
226	Proteomic Insights into Senescence of Testicular Peritubular Cells from a Nonhuman Primate Model. Cells, 2020, 9, 2498.	1.8	7
227	Natural Products Attenuating Biosynthesis, Processing, and Activity of Ras Oncoproteins: State of the Art and Future Perspectives. Biomolecules, 2020, 10, 1535.	1.8	8
228	RasV12 Expression in Microglia Initiates Retinal Inflammation and Induces Photoreceptor Degeneration. , 2020, 61, 34.		8
229	Proximal Protein Interaction Landscape of RAS Paralogs. Cancers, 2020, 12, 3326.	1.7	6
230	M-Ras is Muscle-Ras, Moderate-Ras, Mineral-Ras, Migration-Ras, and Many More-Ras. Experimental Cell Research, 2020, 397, 112342.	1.2	7
231	Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations. Bioinformatics, 2021, 37, 1367-1375.	1.8	6
232	SPRED proteins and their roles in signal transduction, development, and malignancy. Genes and Development, 2020, 34, 1410-1421.	2.7	22
233	Mechanisms of Ras Membrane Organization and Signaling: Ras Rocks Again. Biomolecules, 2020, 10, 1522.	1.8	28
234	Structural basis for the action of the drug trametinib at KSR-bound MEK. Nature, 2020, 588, 509-514.	13.7	86
235	Liver Regeneration after Hepatectomy and Partial Liver Transplantation. International Journal of Molecular Sciences, 2020, 21, 8414.	1.8	69
236	A compendium of mutational cancer driver genes. Nature Reviews Cancer, 2020, 20, 555-572.	12.8	605

#	Article	IF	Citations
237	Functional characterization of a PROTAC directed against BRAF mutant V600E. Nature Chemical Biology, 2020, 16, 1170-1178.	3.9	80
238	A substitution in cGMP-dependent protein kinase 1 associated with aortic disease induces an active conformation in the absence of cGMP. Journal of Biological Chemistry, 2020, 295, 10394-10405.	1.6	11
239	Murine Long Noncoding RNA Morrbid Contributes in the Regulation of NRAS Splicing in Hepatocytes In Vitro. International Journal of Molecular Sciences, 2020, 21, 5605.	1.8	6
240	Study of Ras Mutationsâ€™ Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis. Cancers, 2020, 12, 1919.	1.7	25
241	Structure-based inhibitor design of mutant RAS proteinsâ€”a paradigm shift. Cancer and Metastasis Reviews, 2020, 39, 1091-1105.	2.7	15
242	Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Oncogenic EGFR. Cell Reports, 2020, 32, 107909.	2.9	41
243	Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer and Metastasis Reviews, 2020, 39, 1029-1038.	2.7	149
244	The Myc and Ras Partnership in Cancer: Indistinguishable Alliance or Contextual Relationship?. Cancer Research, 2020, 80, 3799-3802.	0.4	12
245	Cigarette Smoking Is More Prevalent in Patients With Brain Arteriovenous Malformations Compared to General Population: A Cross-Sectional Population-Based Study. Neurosurgery, 2020, 87, E657-E662.	0.6	4
246	Dissemination of RasV12-transformed cells requires the mechanosensitive channel Piezo. Nature Communications, 2020, 11, 3568.	5.8	23
247	Co-Occurring LKB1 Deficiency Determinates the Susceptibility to ERK-Targeted Therapy in RAS-Mutant Lung Cancer. Journal of Thoracic Oncology, 2020, 15, e58-59.	0.5	2
248	Enhanced MAPK1 Function Causes a Neurodevelopmental Disorder within the RASopathy Clinical Spectrum. American Journal of Human Genetics, 2020, 107, 499-513.	2.6	48
249	Multiomics Reveals Ectopic ATP Synthase Blockade Induces Cancer Cell Death via a lncRNA-mediated Phospho-signaling Network. Molecular and Cellular Proteomics, 2020, 19, 1805-1825.	2.5	11
250	Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS . OncoTargets and Therapy, 2020, Volume 13, 10143-10148.	1.0	0
251	Targeting KRAS-Mutant Nonâ€“Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations. Journal of Clinical Oncology, 2020, 38, 4208-4218.	0.8	30
252	Real-Time In-Cell NMR Reveals the Intracellular Modulation of GTP-Bound Levels of RAS. Cell Reports, 2020, 32, 108074.	2.9	26
253	Neuron type-specific expression of a mutant KRAS impairs hippocampal-dependent learning and memory. Scientific Reports, 2020, 10, 17730.	1.6	2
254	Post-translational modification of KRAS: potential targets for cancer therapy. Acta Pharmacologica Sinica, 2021, 42, 1201-1211.	2.8	21

#	Article	IF	Citations
255	Small GTPases of the Ras and Rho Families Switch on/off Signaling Pathways in Neurodegenerative Diseases. International Journal of Molecular Sciences, 2020, 21, 6312.	1.8	49
256	Recent advances in the role of sphingosine 1â€phosphate in cancer. FEBS Letters, 2020, 594, 3583-3601.	1.3	35
257	KRAS^{G12C} Inhibition with Sotorasib in Advanced Solid Tumors. New England Journal of Medicine, 2020, 383, 1207-1217.	13.9	1,049
258	R-Ras GTPases Signaling Role in Myelin Neurodegenerative Diseases. International Journal of Molecular Sciences, 2020, 21, 5911.	1.8	18
259	Novel regulation of Ras proteins by direct tyrosine phosphorylation and dephosphorylation. Cancer and Metastasis Reviews, 2020, 39, 1067-1073.	2.7	18
260	Thiadiazole derivatives as anticancer agents. Pharmacological Reports, 2020, 72, 1079-1100.	1.5	49
261	Inhibitors of BRAF dimers using an allosteric site. Nature Communications, 2020, 11, 4370.	5.8	48
262	The Emerging Role of Ras Pathway Signaling in Pediatric Cancer. Cancer Research, 2020, 80, 5155-5163.	0.4	17
264	NMR in integrated biophysical drug discovery for RAS: past, present, and future. Journal of Biomolecular NMR, 2020, 74, 531-554.	1.6	9
265	Dynamically encoded reactivity of Ras enzymes: opening new frontiers for drug discovery. Cancer and Metastasis Reviews, 2020, 39, 1075-1089.	2.7	16
266	B-Raf-Mutated Melanoma. , 2020, , .		0
267	The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer. Scientific Reports, 2020, 10, 22244.	1.6	9
268	Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology. International Journal of Molecular Sciences, 2020, 21, 8021.	1.8	3
269	Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 338-357.	4.2	96
270	EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. Cancer Discovery, 2020, 10, 1129-1139.	7.7	245
271	A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nature Reviews Immunology, 2020, 20, 651-668.	10.6	2,160
272	Exosomes Derived from the Human Primary Colorectal Cancer Cell Line SW480 Orchestrate Fibroblastâ€Led Cancer Invasion. Proteomics, 2020, 20, e2000016.	1.3	25
273	Capturing the primordial Kras mutation initiating urethane carcinogenesis. Nature Communications, 2020, 11, 1800.	5.8	25

#	Article	IF	Citations
274	Derangement of Metabolic and Lysosomal Gene Profiles in Response to Dexamethasone Treatment in Sarcoidosis. Frontiers in Immunology, 2020, 11, 779.	2.2	5
275	Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 17. Journal of Biological Chemistry, 2020, 295, 9948-9958.	1.6	7
276	Association of KRAS mutation with tumor deposit status and overall survival of colorectal cancer. Cancer Causes and Control, 2020, 31, 683-689.	0.8	7
277	Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application. Journal of Medicinal Chemistry, 2020, 63, 11368-11396.	2.9	128
278	Histology-agnostic drug development â€" considering issues beyond the tissue. Nature Reviews Clinical Oncology, 2020, 17, 555-568.	12.5	60
279	The <scp>RasGEF FgCdc25</scp> regulates fungal development and virulence in <scp>Fusarium graminearum</scp> via <scp>cAMP</scp> and <scp>MAPK</scp> signalling pathways. Environmental Microbiology, 2020, 22, 5109-5124.	1.8	14
280	Senescence as a therapeutically relevant response to CDK4/6 inhibitors. Oncogene, 2020, 39, 5165-5176.	2.6	73
281	Inhibition of NRAS Signaling in Melanoma through Direct Depalmitoylation Using Amphiphilic Nucleophiles. ACS Chemical Biology, 2020, 15, 2079-2086.	1.6	5
282	An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development. Nature Communications, 2020, 11, 2817.	5.8	29
283	Genes, pathways and vulvar carcinoma - New insights from next-generation sequencing studies. Gynecologic Oncology, 2020, 158, 498-506.	0.6	15
284	Swimming toward solutions: Using fish and frogs as models for understanding <scp>RASopathies</scp>. Birth Defects Research, 2020, 112, 749-765.	0.8	10
285	MICA âˆ—012:01 Allele Facilitates the Metastasis of KRAS-Mutant Colorectal Cancer. Frontiers in Genetics, 2020, 11, 511.	1.1	9
286	A conserved, N-terminal tyrosine signal directs Ras for inhibition by Rabex-5. PLoS Genetics, 2020, 16, e1008715.	1.5	7
287	Cancer vaccines: Targeting KRAS-driven cancers. Expert Review of Vaccines, 2020, 19, 163-173.	2.0	30
288	Targeting Kras^{g12c}â€mutant cancer with a mutationâ€specific inhibitor. Journal of Internal Medicine, 2020, 288, 183-191.	2.7	56
289	Monobodies as enabling tools for structural and mechanistic biology. Current Opinion in Structural Biology, 2020, 60, 167-174.	2.6	31
290	Somatic variants in new candidate genes identified in focal cortical dysplasia type II. Epilepsia, 2020, 61, 667-678.	2.6	16
291	The Frequency of Ras Mutations in Cancer. Cancer Research, 2020, 80, 2969-2974.	0.4	515

#	Article	IF	Citations
292	Two Distinct Structures of Membraneâ€Associated Homodimers of GTPâ€•and GDPâ€Bound KRAS4B Revealed by Paramagnetic Relaxation Enhancement. Angewandte Chemie - International Edition, 2020, 59, 11037-11045.	7.2	62
293	Calmodulin disrupts plasma membrane localization of farnesylated KRAS4b by sequestering its lipid moiety. Science Signaling, 2020, 13, .	1.6	23
294	IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models. PLoS ONE, 2020, 15, e0229801.	1.1	4
295	Neurocutaneous disorders. , 2020, , 1-26.		1
296	Nanotechnologies for enhancing cancer immunotherapy. Nano Research, 2020, 13, 2595-2616.	5.8	22
297	Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism. Child's Nervous System, 2020, 36, 2285-2295.	0.6	12
298	Discovery of Novel PDEÎ´ Degraders for the Treatment of KRAS Mutant Colorectal Cancer. Journal of Medicinal Chemistry, 2020, 63, 7892-7905.	2.9	43
299	Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Settingâ€"Role of Academic and Hybrid Modeling. Journal of Clinical Medicine, 2020, 9, 1884.	1.0	5
300	The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cellular and Molecular Immunology, 2020, 17, 807-821.	4.8	1,136
301	Targeted Degradation of Oncogenic KRAS^{G12C} by VHL-Recruiting PROTACs. ACS Central Science, 2020, 6, 1367-1375.	5.3	232
302	Genome-wide DNA methylation analysis of KRAS mutant cell lines. Scientific Reports, 2020, 10, 10149.	1.6	7
303	ssGSEA score-based Ras dependency indexes derived from gene expression data reveal potential Ras addiction mechanisms with possible clinical implications. Scientific Reports, 2020, 10, 10258.	1.6	105
304	Biology, pathology, and therapeutic targeting of RAS. Advances in Cancer Research, 2020, 148, 69-146.	1.9	17
305	Autoimmune lymphoproliferative syndrome. , 2020, , 573-589.		1
306	Intronic CRISPR Repair in a Preclinical Model of Noonan Syndromeâ€"Associated Cardiomyopathy. Circulation, 2020, 142, 1059-1076.	1.6	43
307	Pathogenesis of non-hereditary brain arteriovenous malformation and therapeutic implications. Interventional Neuroradiology, 2020, 26, 244-253.	0.7	8
308	Ferroptosis: Final destination for cancer?. Cell Proliferation, 2020, 53, e12761.	2.4	73
309	Noonan syndrome with multiple Giant cell lesions, management and treatment with surgery and interferon alphaâ€2a therapy: Case report. Birth Defects Research, 2020, 112, 732-739.	0.8	3

#	Article	IF	Citations
310	Ras2, the TC21/R-Ras2 Drosophila homologue, contributes to insulin signalling but is not required for organism viability. Developmental Biology, 2020, 461, 172-183.	0.9	3
311	Oncogenic K-Ras4B Dimerization Enhances Downstream Mitogen-activated Protein Kinase Signaling. Journal of Molecular Biology, 2020, 432, 1199-1215.	2.0	16
312	KRAS: Structure, function, and development of anticancer drugs. , 2020, , 359-389.		0
313	Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants. Trends in Cancer, 2020, 6, 111-129.	3.8	9
314	Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. Cells, 2020, 9, 198.	1.8	314
315	Frequent KRAS mutations in oncocytic papillary renal neoplasm with inverted nuclei. Histopathology, 2020, 76, 1070-1083.	1.6	32
316	Utilities of RAS Mutations in Preoperative Fine Needle Biopsies for Decision Making for Thyroid Nodule Management: Results from a Single-Center Prospective Cohort. Thyroid, 2020, 30, 536-547.	2.4	36
317	Myeloid-derived suppressor cellsâ€"new and exciting players in lung cancer. Journal of Hematology and Oncology, 2020, 13, 10.	6.9	110
318	Oncogenic Signaling Alters Cell Shape and Mechanics to Facilitate Cell Division under Confinement. Developmental Cell, 2020, 52, 563-573.e3.	3.1	65
319	Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS^{G12C}. ChemMedChem, 2020, 15, 827-832.	1.6	20
320	Two Distinct Structures of Membraneâ€Associated Homodimers of GTPâ€•and GDPâ€Bound KRAS4B Revealed by Paramagnetic Relaxation Enhancement. Angewandte Chemie, 2020, 132, 11130-11138.	1.6	5
321	Identification of the Clinical Development Candidate MRTX849, a Covalent KRAS^{G12C} Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry, 2020, 63, 6679-6693.	2.9	300
322	The duality of human oncoproteins: drivers of cancer and congenital disorders. Nature Reviews Cancer, 2020, 20, 383-397.	12.8	44
323	Characterization of Prenylated C-terminal Peptides Using a Thiopropyl-based Capture Technique and LC-MS/MS. Molecular and Cellular Proteomics, 2020, 19, 1005-1016.	2.5	5
324	Cancer stem cell generation by silenced MAPK enhancing PI3K/AKT signaling. Medical Hypotheses, 2020, 141, 109742.	0.8	10
325	A novel terpenoid class for prevention and treatment of KRASâ€driven cancers: Comprehensive analysis using in situ, in vitro, and in vivo model systems. Molecular Carcinogenesis, 2020, 59, 886-896.	1.3	9
326	Presence or Absence of Ras Dimerization Shows Distinct Kinetic Signature in Ras-Raf Interaction. Biophysical Journal, 2020, 118, 1799-1810.	0.2	8
327	A Historic Perspective and Overview of H-Ras Structure, Oncogenicity, and Targeting. Molecular Cancer Therapeutics, 2020, 19, 999-1007.	1.9	14

#	Article	IF	Citations
328	Twenty Years of SynGAP Research: From Synapses to Cognition. Journal of Neuroscience, 2020, 40, 1596-1605.	1.7	96
329	Germline and sporadic cancers driven by the RAS pathway: parallelsÂandÂcontrasts. Annals of Oncology, 2020, 31, 873-883.	0.6	35
330	GLOBAL AND TARGETED PROFILING OF GTPâ€BINDING PROTEINS IN BIOLOGICAL SAMPLES BY MASS SPECTROMETRY. Mass Spectrometry Reviews, 2021, 40, 215-235.	2.8	7
331	Drugging â€œundruggableâ€•genes for cancer treatment: Are we making progress?. International Journal of Cancer, 2021, 148, 8-17.	2.3	63
332	Analysis of Ras-effector interaction competition in large intestine and colorectal cancer context. Small GTPases, 2021, 12, 209-225.	0.7	14
333	DoMY-Seq: A yeast two-hybridâ€“based technique for precision mapping of proteinâ€“protein interaction motifs. Journal of Biological Chemistry, 2021, 296, 100023.	1.6	5
334	Variants of SOS2 are a rare cause of Noonan syndrome with particular predisposition for lymphatic complications. European Journal of Human Genetics, 2021, 29, 51-60.	1.4	17
335	Cancer diagnostics based on plasma protein biomarkers: hard times but great expectations. Molecular Oncology, 2021, 15, 1715-1726.	2.1	46
336	GTPases Arf5 and Arl2 function partially distinctly during oocyte meiosis. Journal of Cellular Biochemistry, 2021, 122, 198-208.	1.2	4
337	Mutation-Specific and Common Phosphotyrosine Signatures of KRAS G12D and G13D Alleles. Journal of Proteome Research, 2021, 20, 670-683.	1.8	12
338	Specific epigenetic microenvironment and the regulation of tumor-related gene expression by trichloroethylene in human hepatocytes. Ecotoxicology and Environmental Safety, 2021, 208, 111453.	2.9	12
339	Genetic Events and Signaling Mechanisms Underlying Schwann Cell Fate in Development and Cancer. Neurosurgery, 2021, 88, 234-245.	0.6	6
340	MageC2 protein is upregulated by oncogenic activation of MAPK pathway and causes impairment of the p53 transactivation function. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 118918.	1.9	3
341	Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer. Nature Cancer, 2021, 2, 49-65.	5.7	54
342	Discoveries in the redox regulation of KRAS. International Journal of Biochemistry and Cell Biology, 2021, 131, 105901.	1.2	2
343	MEK inhibitor resistance mechanisms and recent developments in combination trials. Cancer Treatment Reviews, 2021, 92, 102137.	3.4	85
344	Multiple lentigines in RASA1-associated capillary malformation-arteriovenous malformation syndrome. JAAD Case Reports, 2021, 7, 47-49.	0.4	0
345	LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors. Clinical Cancer Research, 2021, 27, 2061-2073.	3.2	39

#	Article	IF	Citations
346	Coupled membrane lipid miscibility and phosphotyrosine-driven protein condensation phase transitions. Biophysical Journal, 2021, 120, 1257-1265.	0.2	49
347	The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers. Annals of Oncology, 2021, 32, 269-278.	0.6	14
348	Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I. Expert Opinion on Drug Delivery, 2021, 18, 73-102.	2.4	13
349	Small GTPases of the Ras superfamily and glycogen phosphorylase regulation in T cells. Small GTPases, 2021, 12, 106-113.	0.7	10
350	Metabolic Regulator IAPP (Amylin) Is Required for BRAF and RAS Oncogene-Induced Senescence. Molecular Cancer Research, 2021, 19, 874-885.	1.5	2
352	The role of microRNAs in epithelial to mesenchymal transition and cancers; focusing on mir-200 family. Cancer Treatment and Research Communications, 2021, 28, 100385.	0.7	6
353	Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors. OncoImmunology, 2021, 10, 1936757.	2.1	10
354	Alternatives for obtaining a continuous cell line from Apis mellifera. Ciencia Rural, 2021, 51, .	0.3	1
355	The Diagnostic Utility of RAS Q61R Mutation-specific Immunohistochemistry in Epithelial-Myoepithelial Carcinoma. American Journal of Surgical Pathology, 2021, 45, 885-894.	2.1	21
356	Lung cancer molecular mutations and abnormal glycosylation as biomarkers for early diagnosis. Cancer Treatment and Research Communications, 2021, 27, 100311.	0.7	11
357	Oncogenic N-Ras Mitigates Oxidative Stressâ€"Induced Apoptosis of Hematopoietic Stem Cells. Cancer Research, 2021, 81, 1240-1251.	0.4	7
358	Mechanisms of Resistance to KRASG12C Inhibitors. Cancers, 2021, 13, 151.	1.7	81
359	KRAS/BRAF mutations in brain arteriovenous malformations: A systematic review and meta-analysis. Interventional Neuroradiology, 2021, 27, 159101992098281.	0.7	14
360	The Ras dimer structure. Chemical Science, 2021, 12, 8178-8189.	3.7	16
361	Binding of DNA origami to lipids: maximizing yield and switching via strand displacement. Nucleic Acids Research, 2021, 49, 10835-10850.	6.5	17
362	Association Between RAS-Like Proto-Oncogene B (RALB) Gene Expression and Methylation Levels in Saudi Autistic Children. International Journal of Pharmaceutical and Phytopharmacological Research, 2021, 11, 173-176.	0.1	0
363	Novel Finding of Copy Number Gains in GNAS and Loss of 10q in a Child With Malignant Transformation of Neurocutaneous Melanosis Syndrome. JCO Precision Oncology, 2021, 5, 33-38.	1.5	1
364	The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Reports Medicine, 2021, 2, 100186.	3.3	90

#	Article	IF	Citations
365	RASless MEFs as a Tool to Study RAS-Dependent and RAS-Independent Functions. Methods in Molecular Biology, 2021, 2262, 335-346.	0.4	4
366	Liquid droplets of protein LAF1 provide a vehicle to regulate storage of the signaling protein K-Ras4B and its transport to the lipid membrane. Physical Chemistry Chemical Physics, 2021, 23, 5370-5375.	1.3	5
367	Effect of CpG Sites on Transcription Factor in Promoter of â€˜RASA3â€™ Gene. International Journal of Pharmaceutical and Phytopharmacological Research, 2021, 11, 120-124.	0.1	0
368	The i-Motif as a Molecular Target: More Than a Complementary DNA Secondary Structure. Pharmaceuticals, 2021, 14, 96.	1.7	51
369	Roles of palmitoylation in structural long-term synaptic plasticity. Molecular Brain, 2021, 14, 8.	1.3	28
370	Mechanistic insights into the effect of phosphorylation on Ras conformational dynamics and its interactions with cell signaling proteins. Computational and Structural Biotechnology Journal, 2021, 19, 1184-1199.	1.9	51
371	Drug resistance in targeted cancer therapies with RAF inhibitors. , 2021, 4, 665-683.		9
372	Oncogenic KRAS G12D mutation promotes dimerization through a second, phosphatidylserineâ€“dependent interface: a model for KRAS oligomerization. Chemical Science, 2021, 12, 12827-12837.	3.7	19
373	Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer. Advanced Biology, 2021, 5, 1900236.	1.4	13
374	IQGAP3 Overexpression Correlates With Poor Prognosis and Radiation Therapy Resistance in Breast Cancer. Frontiers in Pharmacology, 2020, 11, 584450.	1.6	12
375	KRAS mutation in pancreatic cancer. Seminars in Oncology, 2021, 48, 10-18.	0.8	95
377	Promotion of cancer cell stemness by Ras. Biochemical Society Transactions, 2021, 49, 467-476.	1.6	14
378	The Ins and Outs of RAS Effector Complexes. Biomolecules, 2021, 11, 236.	1.8	27
379	Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity. Cancers, 2021, 13, 778.	1.7	9
380	Targeting the DNA replication stress phenotype of KRAS mutant cancer cells. Scientific Reports, 2021, 11, 3656.	1.6	10
381	The Multi-Level Mechanism of Action of a Pan-Ras Inhibitor Explains its Antiproliferative Activity on Cetuximab-Resistant Cancer Cells. Frontiers in Molecular Biosciences, 2021, 8, 625979.	1.6	7
382	Perspectives on Oncolytic Salmonella in Cancer Immunotherapyâ€”A Promising Strategy. Frontiers in Immunology, 2021, 12, 615930.	2.2	12
384	Targeting KRAS in Colorectal Cancer. Current Oncology Reports, 2021, 23, 28.	1.8	24

#	Article	IF	Citations
385	Targeting RAS phosphorylation in cancer therapy: Mechanisms and modulators. Acta Pharmaceutica Sinica B, 2021, 11, 3433-3446.	5.7	20
386	Linking Metabolic Reprogramming, Plasticity and Tumor Progression. Cancers, 2021, 13, 762.	1.7	22
387	Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer. BMC Cancer, 2021, 21, 193.	1.1	23
388	ERK Inhibitor LY3214996-Based Treatment Strategies forRAS-Driven Lung Cancer. Molecular Cancer Therapeutics, 2021, 20, 641-654.	1.9	16
389	Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. Cancers, 2021, 13, 804.	1.7	76
390	Proteasome regulation by reversible tyrosine phosphorylation at the membrane. Oncogene, 2021, 40, 1942-1956.	2.6	7
391	KRAS gene polymorphisms are associated with the risk of glioma: a two-center case-control study. Translational Pediatrics, 2021, 10, 579-586.	0.5	7
392	The metabolic landscape of RAS-driven cancers from biology to therapy. Nature Cancer, 2021, 2, 271-283.	5.7	139
393	Targeting KRAS in Cancer: Promising Therapeutic Strategies. Cancers, 2021, 13, 1204.	1.7	40
394	Structural Determinants for Light-Dependent Membrane Binding of a Photoswitchable Polybasic Domain. ACS Synthetic Biology, 2021, 10, 542-551.	1.9	7
395	Quantitative Proteomic Analysis in Alveolar Type II Cells Reveals the Different Capacities of RAS and TGF-Î² to Induce Epithelialâ€“Mesenchymal Transition. Frontiers in Molecular Biosciences, 2021, 8, 595712.	1.6	5
396	Palmitoylation as a Key Regulator of Ras Localization and Function. Frontiers in Molecular Biosciences, 2021, 8, 659861.	1.6	28
397	Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs). Pharmacological Research, 2021, 165, 105422.	3.1	46
398	Signaling pathways in intestinal homeostasis and colorectal cancer: KRAS at centre stage. Cell Communication and Signaling, 2021, 19, 31.	2.7	19
399	An Integrative Transcriptome-Wide Analysis of Amyotrophic Lateral Sclerosis for the Identification of Potential Genetic Markers and Drug Candidates. International Journal of Molecular Sciences, 2021, 22, 3216.	1.8	12
400	If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 3025.	1.8	5
402	A Leucine-Rich Repeat Protein Provides a SHOC2 the RAS Circuit: a Structure-Function Perspective. Molecular and Cellular Biology, 2021, 41, .	1.1	15
403	The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. Nature Communications, 2021, 12, 1808.	5.8	90

#	Article	IF	Citations
404	Diffusion-based determination of protein homodimerization on reconstituted membrane surfaces. BMB Reports, 2021, 54, 157-163.	1.1	1
405	Resistance to Molecularly Targeted Therapies in Melanoma. Cancers, 2021, 13, 1115.	1.7	36
406	Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico. Biomolecules, 2021, 11, 518.	1.8	4
407	RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. European Journal of Cancer, 2021, 146, 74-83.	1.3	29
408	Aberrant phase separation and cancer. FEBS Journal, 2022, 289, 17-39.	2.2	42
409	Concomitant Mutations G12D and G13D on the Exon 2 of the KRAS Gene: Two Cases of Women with Colon Adenocarcinoma. Diagnostics, 2021, 11, 659.	1.3	4
410	Rational antibody design for undruggable targets using kinetically controlled biomolecular probes. Science Advances, 2021, 7, .	4.7	3
411	An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances. Pharmaceuticals, 2021, 14, 316.	1.7	13
412	Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling. Genes, 2021, 12, 553.	1.0	13
413	Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 4012-4024.	3.2	20
414	Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells. Cancer Gene Therapy, 2022, 29, 505-518.	2.2	14
415	Machine-learning-based dynamic-importance sampling for adaptive multiscale simulations. Nature Machine Intelligence, 2021, 3, 401-409.	8.3	22
416	Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition. Cancers, 2021, 13, 1852.	1.7	3
417	Nucleotide variation in histone H2BL drives crosstalk of histone modification and promotes tumour cell proliferation by upregulating c-Myc. Life Sciences, 2021, 271, 119127.	2.0	0
418	Rasâ€“guanine nucleotide complexes: A UV spectral deconvolution method to analyze protein concentration, nucleotide stoichiometry, and purity. Analytical Biochemistry, 2021, 618, 114066.	1.1	3
419	Prognostic value of KRAS mutation in patients undergoing pulmonary metastasectomy for colorectal cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 160, 103308.	2.0	9
420	Understand KRAS and the Quest for Anti-Cancer Drugs. Cells, 2021, 10, 842.	1.8	10
421	Pulmonary metastasectomy in colorectal carcinoma. Journal of Thoracic Disease, 2021, 13, 2628-2635.	0.6	11

#	Article	IF	Citations
422	Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 Inhibition. SLAS Discovery, 2021, 26, 922-932.	1.4	1
423	Precision oncology in metastatic colorectal cancer â€" from biology to medicine. Nature Reviews Clinical Oncology, 2021, 18, 506-525.	12.5	113
424	Mechanistic Insight on Ras Inhibition Strategies in Cancer Therapy. Pharmaceutical Sciences, 2021, , .	0.1	0
425	Vitamin E succinate with multiple functions: A versatile agent in nanomedicine-based cancer therapy and its delivery strategies. International Journal of Pharmaceutics, 2021, 600, 120457.	2.6	14
427	Molecular Biology of Pediatric and Adult Male Germ Cell Tumors. Cancers, 2021, 13, 2349.	1.7	9
428	A structural perspective on targeting the <scp>RTK</scp>/Ras/<scp>MAP</scp> kinase pathway in cancer. Protein Science, 2021, 30, 1535-1553.	3.1	17
429	KRAS G12Câ€"Mutant Nonâ€"Small Cell Lung Cancer. Journal of Molecular Diagnostics, 2021, 23, 507-520.	1.2	40
430	The Crossroads between RAS and RHO Signaling Pathways in Cellular Transformation, Motility and Contraction. Genes, 2021, 12, 819.	1.0	35
431	LZTR1: A promising adaptor of the CUL3 family (Review). Oncology Letters, 2021, 22, 564.	0.8	13
432	KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From InÂVitro Experiments. Journal of Thoracic Oncology, 2021, 16, 1321-1332.	0.5	118
434	The Role of the Guanosine Nucleotide-Binding Protein in the Corpus Luteum. Animals, 2021, 11, 1524.	1.0	1
435	Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	16
436	Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents. Bioorganic Chemistry, 2021, 110, 104825.	2.0	12
437	Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations. Frontiers in Endocrinology, 2021, 12, 678869.	1.5	3
438	Targeting the KRAS Î±4-Î±5 allosteric interface inhibits pancreatic cancer tumorigenesis. Small GTPases, 2021, , 1-14.	0.7	11
439	Twist1 sustains the apoptosis resistance in eosinophils in nasal mucosa of allergic rhinitis. Archives of Biochemistry and Biophysics, 2021, 702, 108828.	1.4	5
440	A Computational Framework to Identify Cross Association Between Complex Disorders by Protein-protein Interaction Network Analysis. Current Bioinformatics, 2021, 16, 433-445.	0.7	6
441	Selective and noncovalent targeting of RAS mutants for inhibition and degradation. Nature Communications, 2021, 12, 2656.	5.8	51

#	Article	IF	Citations
442	BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer. Molecular and Cellular Biochemistry, 2021, 476, 3469-3482.	1.4	4
443	Ras, TrkB, and ShcA Protein Expression Patterns in Pediatric Brain Tumors. Journal of Clinical Medicine, 2021, 10, 2219.	1.0	0
444	In vivo Functional Genomics for Undiagnosed Patients: The Impact of Small GTPases Signaling Dysregulation at Pan-Embryo Developmental Scale. Frontiers in Cell and Developmental Biology, 2021, 9, 642235.	1.8	3
445	RAF-MEK-ERK pathway in cancer evolution and treatment. Seminars in Cancer Biology, 2022, 85, 123-154.	4.3	113
446	Ras Isoforms from Lab Benches to Livesâ€"What Are We Missing and How Far Are We?. International Journal of Molecular Sciences, 2021, 22, 6508.	1.8	5
449	Cross the Undruggable Barrier, the Development of SHP2 Inhibitors: From Catalytic Site Inhibitors to Allosteric Inhibitors. ChemistrySelect, 2021, 6, 5504-5523.	0.7	3
450	Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma. OncoTargets and Therapy, 2021, Volume 14, 3709-3719.	1.0	24
451	Accessory proteins of the RAS-MAPK pathway: moving from the side line to the front line. Communications Biology, 2021, 4, 696.	2.0	32
452	The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. Frontiers in Oncology, 2021, 11, 641428.	1.3	32
453	WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth. Oncogene, 2021, 40, 4229-4241.	2.6	7
454	Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment. Current Opinion in Chemical Biology, 2021, 62, 1-12.	2.8	83
455	Nonclinical Safety Profile of Sotorasib, a KRAS^{G12C}-Specific Covalent Inhibitor for the Treatment of KRAS p.G12C-Mutated Cancer. International Journal of Toxicology, 2021, 40, 427-441.	0.6	6
456	Strategies to tackle RAS-mutated metastatic colorectal cancer. ESMO Open, 2021, 6, 100156.	2.0	38
457	Inhibition of Ras and STAT3 activity of 4-(tert-butyl)-N-carbamoylbenzamide as antiproliferative agent in HER2-expressing breast cancer cells. Journal of Basic and Clinical Physiology and Pharmacology, 2021, 32, 363-371.	0.7	1
458	Clinicopathological analysis and genomic profiling of a rare histiocyte-rich rhabdomyoblastic tumor. Medicine (United States), 2021, 100, e26105.	0.4	5
459	Development of a High-throughput NanoBRET Screening Platform to Identify Modulators of the RAS/RAF Interaction. Molecular Cancer Therapeutics, 2021, 20, 1743-1754.	1.9	7
460	Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies. Pharmacological Research, 2021, 168, 105579.	3.1	39
461	Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, and Proteolysis-Targeting Chimeras: The Pharmacology of Cutting-Edge Lung Cancer Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e286-e293.	1.8	2

#	Article	IF	Citations
462	RAS-inhibiting biologics identify and probe druggable pockets including an SII-Î±3 allosteric site. Nature Communications, 2021, 12, 4045.	5.8	19
463	Signaling pathways and defense mechanisms of ferroptosis. FEBS Journal, 2022, 289, 7038-7050.	2.2	177
464	Is This the Dawn of Precision Oncology in Head and Neck Cancer?. Journal of Clinical Oncology, 2021, 39, 1839-1841.	0.8	1
465	Kras activation in endometrial organoids drives cellular transformation and epithelial-mesenchymal transition. Oncogenesis, 2021, 10, 46.	2.1	11
466	Mini review: The FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancer. Breast Disease, 2021, 40, 51-62.	0.4	15
467	Facile Synthesis of Boc-Protected Selenocystine and its Compatibility with Late-Stage Farnesylation at Cysteine Site. Protein and Peptide Letters, 2021, 28, 603-611.	0.4	0
468	KRAS phosphorylation regulates cell polarization and tumorigenic properties in colorectal cancer. Oncogene, 2021, 40, 5730-5740.	2.6	5
470	KRAS-targeted therapies in advanced solid cancers: drug the undruggable?. Pharmacogenomics, 2021, 22, 587-590.	0.6	5
471	Expanding TOR Complex 2 Signaling: Emerging Regulators and New Connections. Frontiers in Cell and Developmental Biology, 2021, 9, 713806.	1.8	5
472	Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nature Communications, 2021, 12, 4365.	5.8	53
473	Divergent Mechanisms Activating RAS and Small GTPases Through Post-translational Modification. Frontiers in Molecular Biosciences, 2021, 8, 707439.	1.6	13
474	Endonuclease IV-Regulated DNAzyme Motor for Universal Single-nucleotide Variation Discrimination. Analytical Chemistry, 2021, 93, 9939-9948.	3.2	11
475	Integrated in silico MS-based phosphoproteomics and network enrichment analysis of RASopathy proteins. Orphanet Journal of Rare Diseases, 2021, 16, 303.	1.2	1
476	Opposite functions of RapA and RapC in cell adhesion and migration in Dictyostelium. Animal Cells and Systems, 2021, 25, 203-210.	0.8	4
477	KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	9
478	The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study. Oncologist, 2021, 26, 845-853.	1.9	26
479	The Importance of Being PI3K in the RAS Signaling Network. Genes, 2021, 12, 1094.	1.0	28
480	Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. Journal of Hematology and Oncology, 2021, 14, 108.	6.9	127

#	Article	IF	Citations
481	Current Treatment of Juvenile Myelomonocytic Leukemia. Journal of Clinical Medicine, 2021, 10, 3084.	1.0	20
482	Peptide-tiling screens of cancer drivers reveal oncogenic protein domains and associated peptide inhibitors. Cell Systems, 2021, 12, 716-732.e7.	2.9	9
483	Ras Family of Small GTPases in CRC: New Perspectives for Overcoming Drug Resistance. Cancers, 2021, 13, 3757.	1.7	3
484	Broadening COVID-19 Interventions to Drug Innovation: Neprilysin Pathway as a Friend, Foe, or Promising Molecular Target?. OMICS A Journal of Integrative Biology, 2021, 25, 408-416.	1.0	5
485	Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition. Cancers, 2021, 13, 3464.	1.7	5
486	Novel insights into the pathogenesis and treatment of NRAS mutant melanoma. Expert Review of Precision Medicine and Drug Development, 2021, 6, 281-294.	0.4	4
487	Lysine Fatty Acylation: Regulatory Enzymes, Research Tools, and Biological Function. Frontiers in Cell and Developmental Biology, 2021, 9, 717503.	1.8	14
488	Colorectal Cancer, Liver Metastases and Biotherapies. Biomedicines, 2021, 9, 894.	1.4	5
489	Cancer - dysregulation of the cell cycle and transduction of cascade signals. Romanian Journal of Rhinology, 2021, 11, 90-100.	0.1	0
490	Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature. Expert Opinion on Therapeutic Patents, 2021, 31, 1189-1204.	2.4	14
491	Toward Understanding the Mechanisms of Malignant Peripheral Nerve Sheath Tumor Development. International Journal of Molecular Sciences, 2021, 22, 8620.	1.8	14
492	Discovery of a Bicyclic Peptidyl Pan-Ras Inhibitor. Journal of Medicinal Chemistry, 2021, 64, 13038-13053.	2.9	15
493	Gene expression profile analysis of gallic acid-induced cell death process. Scientific Reports, 2021, 11, 16743.	1.6	4
494	Development and Preclinical Evaluation of Radiolabeled Covalent G12C-Specific Inhibitors for Direct Imaging of the Oncogenic KRAS Mutant. Molecular Pharmaceutics, 2021, 18, 3509-3518.	2.3	2
495	RAS interaction with Sin1 is dispensable for mTORC2 assembly and activity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	21
496	Discovery of a dual Ras and ARF6 inhibitor from a GPCR endocytosis screen. Nature Communications, 2021, 12, 4688.	5.8	7
497	Multiple versus solitary giant cell lesions of the jaw: Similar or distinct entities?. Bone, 2021, 149, 115935.	1.4	10
498	KRAS Inhibitor Resistance in MET-Amplified KRASG12C Nonâ€“Small Cell Lung Cancer Induced By RAS- and Nonâ€“RAS-Mediated Cell Signaling Mechanisms. Clinical Cancer Research, 2021, 27, 5697-5707.	3.2	42

#	Article	IF	Citations
499	Synthetic and Chromatographic Challenges and Strategies for Multigram Manufacture of KRAS^{G12C} Inhibitors. Organic Process Research and Development, 2022, 26, 710-729.	1.3	12
500	Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer. Nature Communications, 2021, 12, 4789.	5.8	21
501	KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine. Expert Opinion on Biological Therapy, 2021, 21, 1325-1334.	1.4	4
502	Prospective Evaluation of Radiotherapy-Induced Immunologic and Genetic Effects in Colorectal Cancer Oligo-Metastatic Patients with Lung-Limited Disease: The PRELUDE-1 Study. Cancers, 2021, 13, 4236.	1.7	8
503	NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?â€"Case series and review of the literature. European Journal of Cancer, 2021, 153, 86-95.	1.3	16
504	Reversible function of RapA with the C-terminus of RapC in Dictyostelium. Journal of Microbiology, 2021, 59, 848-853.	1.3	1
505	ZNF768 links oncogenic RAS to cellular senescence. Nature Communications, 2021, 12, 4841.	5.8	11
506	The KRAS-G12C inhibitor: activity and resistance. Cancer Gene Therapy, 2022, 29, 875-878.	2.2	69
508	The RAS GTPase RIT1 compromises mitotic fidelity through spindle assembly checkpoint suppression. Current Biology, 2021, 31, 3915-3924.e9.	1.8	14
509	Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing Î²-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway. Bioengineered, 2021, 12, 8296-8308.	1.4	4
510	Membrane-bound KRAS approximates an entropic ensemble of configurations. Biophysical Journal, 2021, 120, 4055-4066.	0.2	1
511	Systematic discovery and validation of TÂcell targets directed against oncogenic KRAS mutations. Cell Reports Methods, 2021, 1, 100084.	1.4	24
512	KRAS-related long noncoding RNAs in human cancers. Cancer Gene Therapy, 2022, 29, 418-427.	2.2	8
513	Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Annals of Oncology, 2021, 32, 1101-1110.	0.6	134
514	Targeting steroid hormone receptors for antiâ€cancer therapyâ€"A review on small molecules and nanotherapeutic approaches. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, 14, e1755.	3.3	9
515	NRAS mutant melanoma: Towards better therapies. Cancer Treatment Reviews, 2021, 99, 102238.	3.4	56
516	Potential Effects of Coronaviruses on the Liver: An Update. Frontiers in Medicine, 2021, 8, 651658.	1.2	38
517	Targeting the actin nucleation promoting factor WASp provides a therapeutic approach for hematopoietic malignancies. Nature Communications, 2021, 12, 5581.	5.8	8

#	Article	IF	Citations
518	Neofunctionalization of an ancient domain allows parasites to avoid intraspecific competition by manipulating host behaviour. Nature Communications, 2021, 12, 5489.	5.8	15
519	EGFR-RAS-MAPK signaling is confined to the plasma membrane and associated endorecycling protrusions. Journal of Cell Biology, 2021, 220, .	2.3	15
520	Allosteric MEK inhibitors act on BRAF/MEK complexes to block MEK activation. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	23
521	Transgenic mouse models of breast cancer. Cancer Letters, 2021, 516, 73-83.	3.2	7
522	Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy. Acta Pharmaceutica Sinica B, 2021, 11, 2738-2748.	5.7	12
523	Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nature Reviews Clinical Oncology, 2022, 19, 37-50.	12.5	350
526	KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin. Cancer Letters, 2021, 517, 66-77.	3.2	22
527	Genomic Landscape of Malignant Peripheral Nerve Sheath Tumorâ€'Like Melanoma. Journal of Investigative Dermatology, 2021, 141, 2470-2479.	0.3	1
528	Allosteric Switching of Calmodulin in a Mycobacterium smegmatis porinâ€...A (MspA) Nanoporeâ€Trap. Angewandte Chemie, 2021, 133, 24056.	1.6	5
529	HPLC method to resolve, identify and quantify guanine nucleotides bound to recombinant ras GTPase. Analytical Biochemistry, 2021, 631, 114338.	1.1	3
530	Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS. Pharmacological Research, 2021, 172, 105806.	3.1	17
531	Allosteric Switching of Calmodulin in a Mycobacterium smegmatis porinâ€...A (MspA) Nanoporeâ€Trap. Angewandte Chemie - International Edition, 2021, 60, 23863-23870.	7.2	25
532	New insights into Raf regulation from structural analyses. Current Opinion in Structural Biology, 2021, 71, 223-231.	2.6	4
533	Developments of CRBN-based PROTACs as potential therapeutic agents. European Journal of Medicinal Chemistry, 2021, 225, 113749.	2.6	64
534	Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells. Translational Oncology, 2021, 14, 101230.	1.7	10
535	NF-ÎºB-inducing kinase maintains T cell metabolic fitness in antitumor immunity. Nature Immunology, 2021, 22, 193-204.	7.0	52
536	Cisplatin and Pemetrexed Have Distinctive Growth-inhibitory Effects in Monotherapy and Combination Therapy on KRAS-dependent A549 Lung Cancer Cells. Cancer Genomics and Proteomics, 2021, 18, 579-590.	1.0	2
537	A comprehensive analysis of RAS-effector interactions reveals interaction hotspots and new binding partners. Journal of Biological Chemistry, 2021, 296, 100626.	1.6	14

#	Article	IF	Citations
538	Production and Membrane Binding of N-Terminally Acetylated, C-Terminally Farnesylated and Carboxymethylated KRAS4b. Methods in Molecular Biology, 2021, 2262, 105-116.	0.4	1
539	Oncogenic Ras Disrupts Epithelial Integrity by Activating the Transmembrane Serine Protease Hepsin. Cancer Research, 2021, 81, 1513-1527.	0.4	10
540	Proteins moonlighting in tumor metabolism and epigenetics. Frontiers of Medicine, 2021, 15, 383-403.	1.5	12
541	Ras and Ras Signaling as a Therapeutic Target in Cancer. , 2021, , .		0
542	Molecular basis for Ras suppressor-1 binding to PINCH-1 in focal adhesion assembly. Journal of Biological Chemistry, 2021, 296, 100685.	1.6	5
543	Endolysosomal TRPMLs in Cancer. Biomolecules, 2021, 11, 65.	1.8	17
545	Biology of Melanocytes and Primary Melanoma. , 2020, , 3-40.		4
546	Mechanisms and Markers of Clinical Radioresistance. Cancer Drug Discovery and Development, 2020, , 63-96.	0.2	1
547	Overcoming Resistance to Drugs Targeting KRAS Mutation. Innovation(China), 2020, 1, 100035.	5.2	44
548	Optogenetic regulation of endogenous proteins. Nature Communications, 2020, 11, 605.	5.8	39
549	RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics. Biochemical Journal, 2020, 477, 2893-2919.	1.7	12
550	The molecular functions of RIT1 and its contribution to human disease. Biochemical Journal, 2020, 477, 2755-2770.	1.7	11
551	Inhibition of RAS: proven and potential vulnerabilities. Biochemical Society Transactions, 2020, 48, 1831-1841.	1.6	15
552	Inhibition of RAF dimers: it takes two to tango. Biochemical Society Transactions, 2021, 49, 237-251.	1.6	35
553	SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. Journal of Experimental Medicine, 2021, 218, .	4.2	138
554	Merlin cooperates with neurofibromin and Spred1 to suppress the Rasâ€“Erk pathway. Human Molecular Genetics, 2021, 29, 3793-3806.	1.4	7
566	Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview. Cancer Science, 2020, 111, 1076-1083.	1.7	12
567	A massively parallel infrastructure for adaptive multiscale simulations. , 2019, , .		32

#	Article	IF	Citations
568	Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. Journal of Clinical Investigation, 2020, 130, 1752-1766.	3.9	200
569	A subset of flavaglines inhibits KRAS nanoclustering and activation. Journal of Cell Science, 2020, 133, .	1.2	10
570	Orai1 Promotes Osteosarcoma Metastasis by Activating the Ras-Rac1-WAVE2 Signaling Pathway. Medical Science Monitor, 2019, 25, 9227-9236.	0.5	8
571	Development of a cell-free split-luciferase biochemical assay as a tool for screening for inhibitors of challenging protein-protein interaction targets. Wellcome Open Research, 2020, 5, 20.	0.9	14
572	Pituitary stalk interruption syndrome is characterized by genetic heterogeneity. PLoS ONE, 2020, 15, e0242358.	1.1	26
573	Epigenetic changes in fibroblasts drive cancer metabolism and differentiation. Endocrine-Related Cancer, 2019, 26, R673-R688.	1.6	34
574	High expression of UNC5B enhances tumor proliferation, increases metastasis, and worsens prognosis in breast cancer. Aging, 2020, 12, 17079-17098.	1.4	12
575	From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers. Cancer Biology and Medicine, 2019, 16, 435-461.	1.4	15
576	The Function of RAS Mutation in Cancer and Advances in its Drug Research. Current Pharmaceutical Design, 2019, 25, 1105-1114.	0.9	53
577	Overview of Current Immunotherapies Targeting Mutated KRAS Cancers. Current Topics in Medicinal Chemistry, 2019, 19, 2158-2175.	1.0	4
578	The immunoreactivity of the anti-p21Ras single-chain fragment variant KGH-R1 and its predicted binding sites to p21Ras. Immunotherapy, 2020, 12, 879-890.	1.0	3
579	The hypoxia-response pathway modulates RAS/MAPKâ€“mediated cell fate decisions inCaenorhabditis elegans. Life Science Alliance, 2019, 2, e201800255.	1.3	14
580	Antiangiogenic agent as a novel treatment for pediatric intracranial arteriovenous malformations: case report. Journal of Neurosurgery: Pediatrics, 2019, 24, 673-679.	0.8	7
581	Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development. Processes, 2021, 9, 71.	1.3	162
582	ERK/MAPK signalling pathway and tumorigenesis (Review). Experimental and Therapeutic Medicine, 2020, 19, 1997-2007.	0.8	670
583	Human endogenous retroviruses in cancer: Expression, regulation and function (Review). Oncology Letters, 2020, 21, 121.	0.8	29
584	G proteins: binary switches in health and disease. Central-European Journal of Immunology, 2020, 45, 364-367.	0.4	2
585	Role of estrogen and RAS signaling in repeated implantation failure. BMB Reports, 2018, 51, 225-229.	1.1	21

#	Article	IF	Citations
586	Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells. ELife, 2018, 7, .	2.8	70
587	RalB directly triggers invasion downstream Ras by mobilizing the Wave complex. ELife, 2018, 7, .	2.8	27
588	High-throughput, single-particle tracking reveals nested membrane domains that dictate KRasG12D diffusion and trafficking. ELife, 2019, 8, .	2.8	40
589	Membrane interactions of the globular domain and the hypervariable region of KRAS4b define its unique diffusion behavior. ELife, 2020, 9, .	2.8	23
590	SynGAP isoforms differentially regulate synaptic plasticity and dendritic development. ELife, 2020, 9, .	2.8	60
591	Biomarkers. UNIPA Springer Series, 2021, , 43-64.	0.1	0
592	Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer. Cancer Biology and Medicine, 2021, 18, 0-0.	1.4	4
593	Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges. Molecular Cancer, 2021, 20, 128.	7.9	41
594	A structural model of a Rasâ€“Raf signalosome. Nature Structural and Molecular Biology, 2021, 28, 847-857.	3.6	44
595	Channeling the Force: Piezo1 Mechanotransduction in Cancer Metastasis. Cells, 2021, 10, 2815.	1.8	34
596	Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance. Cancers, 2021, 13, 5126.	1.7	18
597	Kirsten rat sarcoma inhibitors in clinical development against nonsmall cell lung cancer. Current Opinion in Oncology, 2022, 34, 66-76.	1.1	3
598	Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT signaling and promotes prostate tumorigenesis. Cell Reports, 2021, 37, 109870.	2.9	15
599	The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS. Science, 2021, 374, 197-201.	6.0	35
600	Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. Journal of Clinical Investigation, 2021, 131, .	3.9	15
601	Exploiting cancerâ€™s drinking problem: regulation and therapeutic potential of macropinocytosis. Trends in Cancer, 2022, 8, 54-64.	3.8	23
602	SPRED2 loss-of-function causes a recessive Noonan syndrome-like phenotype. American Journal of Human Genetics, 2021, 108, 2112-2129.	2.6	23
603	Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers. Cancers, 2021, 13, 5081.	1.7	13

#	Article	IF	Citations
604	Novel genomics insights into body size evolution in cetaceans and the resolution of Peto's paradox. American Naturalist, 2022, 199, E28-E42.	1.0	2
605	DIRAS3: An Imprinted Tumor Suppressor Gene that Regulates RAS and PI3K-driven Cancer Growth, Motility, Autophagy, and Tumor Dormancy. Molecular Cancer Therapeutics, 2022, 21, 25-37.	1.9	20
606	After decades, RAS mutation has finally become a therapeutic target. Personalized Medicine, 2021, 18, 523-525.	0.8	0
607	The fellowship of the RING: BRCA1, its partner BARD1 and their liaison in DNA repair and cancer. , 2022, 232, 108009.		3
608	Generalizable coordination of large multiscale workflows. , 2021, , .		17
609	HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2. European Journal of Cancer, 2021, 159, 16-23.	1.3	23
610	Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity. Bioorganic Chemistry, 2021, 117, 105447.	2.0	15
616	Biology of Melanocytes and Primary Melanoma. , 2019, , 1-38.		0
617	Blocking KRAS Signaling for the Treatment of Lung Cancer: Mission Possible?. Japanese Journal of Lung Cancer, 2018, 58, 953-958.	0.0	0
618	CD146 Regulates Growth Factor-Induced mTORC2 Activity Independent of PI3K and mTORC1 Pathways. SSRN Electronic Journal, 0, , .	0.4	0
625	MappingÂthe Radiogenome of Human Cancers. Cancer Drug Discovery and Development, 2020, , 35-61.	0.2	0
630	Development of a cell-free split-luciferase biochemical assay as a tool for screening for inhibitors of challenging protein-protein interaction targets. Wellcome Open Research, 0, 5, 20.	0.9	0
632	Influence of Cold Ischemia Time and Storage Period on DNA Quality and Biomarker Research in Biobanked Colorectal Cancer Tissues. Kosin Medical Journal, 2020, 35, 26-37.	0.1	2
635	KRas4BG12C/D/PDE6Î´ Heterodimeric Molecular Complex: A Target Molecular Multicomplex for the Identification and Evaluation of Nontoxic Pharmacological Compounds for the Treatment of Pancreatic Cancer. , 0, , .		2
637	Histopathology and Molecular Pathology of Craniopharyngioma in Adults. , 2020, , 1-17.		2
640	Genetics and Pathway in Neurofibromatosis Type 1. , 2020, , 5-14.		1
643	VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives. European Journal of Medicinal Chemistry, 2022, 227, 113906.	2.6	27
644	Chapter 13. The Posttranslational Cysteinyl Proteome. Chemical Biology, 2020, , 313-357.	0.1	0

#	Article	IF	Citations
645	Clinical orofacial and myofunctional manifestations in an adolescent with Noonan Syndrome: a case report. Revista CEFAC: ActualizaÃ§Ã£o CientÃfica Em Fonoaudiologia, 2020, 22, .	0.2	1
646	Molecular Simulations of Biological Nanoswitches. , 2020, , 1-5.		1
649	Relating cellular signaling timescales to single-molecule kinetics: A first-passage time analysis of Ras activation by SOS. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	9
650	Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Molecular Cancer, 2021, 20, 143.	7.9	117
651	A method establishment and comparison of in vivo lung cancer model development platforms for evaluation of tumour metabolism and pharmaceutical efficacy. Phytomedicine, 2021, 96, 153831.	2.3	1
652	TGFB3-AS1 promotes Hcy-induced inflammation of macrophages via inhibiting the maturity of miR-144 and upregulating Rap1a. Molecular Therapy - Nucleic Acids, 2021, 26, 1318-1335.	2.3	2
655	Comparative MD simulations and advanced analytics based studies on wild-type and hot-spot mutant A59G HRas. PLoS ONE, 2020, 15, e0234836.	1.1	4
659	Signal Transduction in Hepatocellular Carcinoma: Insights from Zebrafish. Proceedings of the Singapore National Academy of Science, 2020, 14, 47-58.	0.1	0
660	KRAS mutations are negatively correlated with immunity in colon cancer. Aging, 2021, 13, 750-768.	1.4	10
662	Upregulation of GTPBP4 Promotes the Proliferation of Liver Cancer Cells. Journal of Oncology, 2021, 2021, 1049104.	0.6	0
664	Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature, 2021, 599, 679-683.	13.7	183
665	Concurrent Disruption of the Ras/MAPK and NF-ÎºB Pathways Induces Circadian Deregulation and Hepatocarcinogenesis. Molecular Cancer Research, 2022, 20, 337-349.	1.5	6
666	A Clinical Evaluation of Circulating MiR-106a and Raf-1 as Breast Cancer Diagnostic and Prognostic Markers. Asian Pacific Journal of Cancer Prevention, 2021, 22, 3513-3520.	0.5	8
667	Therapeutic Response-Based Reclassification of Multiple Tumor Subtypes Reveals Intrinsic Molecular Concordance of Therapy Across Histologically Disparate Cancers. Frontiers in Cell and Developmental Biology, 2021, 9, 773101.	1.8	0
668	Dynamic CD4+ T cell heterogeneity defines subset-specific suppression and PD-L1-blockade-driven functional restoration in chronic infection. Nature Immunology, 2021, 22, 1524-1537.	7.0	26
669	Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry. Targeted Oncology, 2022, 17, 35-41.	1.7	3
670	Oncogenic KRAS: Signaling and Drug Resistance. Cancers, 2021, 13, 5599.	1.7	25
671	A mechanistic basis for the malignant progression of salivary gland tumors. IScience, 2021, 24, 103508.	1.9	1

#	Article	IF	Citations
672	Editorial: Ras and Other GTPases in Cancer: From Basic to Applied Research. Frontiers in Molecular Biosciences, 2021, 8, 804818.	1.6	0
673	KRAS A146 Mutations Are Associated With Distinct Clinical Behavior in Patients With Colorectal Liver Metastases. JCO Precision Oncology, 2021, 5, 1758-1767.	1.5	9
674	Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer. International Journal of Molecular Sciences, 2021, 22, 12402.	1.8	8
676	Phenotype from SAMD9 Mutation at 7p21.2 Appears Attenuated by Novel Compound Heterozygous Variants at RUNX2 and SALL1. Global Medical Genetics, 2022, 09, 124-128.	0.4	3
677	Elucidating microscopic events driven by GTP hydrolysis reaction in the Rasâ€“GAP system with semi-reactive molecular dynamics simulations: the alternative role of a phosphate binding loop for mechanical energy storage. Physical Chemistry Chemical Physics, 2021, 23, 26151-26164.	1.3	3
678	Clinical Implication of KRAS Mutation Variants in Patients With Resected Colon Cancer. Cancer Diagnosis & Prognosis, 2022, 2, 78-83.	0.3	1
679	Targeting the undruggable oncogenic KRAS: the dawn of hope. JCI Insight, 2022, 7, .	2.3	27
681	Lymphangiography as a Treatment for Refractory Congenital Chylothorax Due to RASopathies: A Report of Two Cases. Interventional Radiology, 2022, , .	0.2	0
682	In silico comparative analysis of KRAS mutations at codons 12 and 13: Structural modifications of P-Loop, switch I&II regions preventing GTP hydrolysis. Computers in Biology and Medicine, 2022, 141, 105110.	3.9	4
683	A method of delivering an anti-p21Ras single-chain antibody fragment to tumor sites in vivo. Journal of Drug Delivery Science and Technology, 2022, 68, 103024.	1.4	1
684	Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC. European Journal of Medicinal Chemistry, 2022, 230, 114088.	2.6	39
685	Biochemical characterization of the interaction between KRAS and Argonaute 2. Biochemistry and Biophysics Reports, 2022, 29, 101191.	0.7	5
686	Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations. Healthbook TIMES Oncology Hematology, 2020, , .	0.1	3
687	Upregulation of GTPBP4 Promotes the Proliferation of Liver Cancer Cells. Journal of Oncology, 2021, 2021, 1-10.	0.6	7
688	FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC. Clinical Cancer Research, 2022, 28, 1482-1486.	3.2	128
689	NMNAT promotes glioma growth through regulating post-translational modifications of P53 to inhibit apoptosis. ELife, 2021, 10, .	2.8	13
691	Patterning of Oncogenic Ras Clustering in Live Cells Using Vertically Aligned Nanostructure Arrays. Nano Letters, 2022, 22, 1007-1016.	4.5	7
692	Development of a biotinâ€“streptavidin-enhanced enzyme-linked immunosorbent assay (BA-ELISA) for high-throughput screening of KRASG12C inhibitors. SLAS Discovery, 2022, , .	1.4	0

#	Article	IF	Citations
693	Tcof1 haploinsufficiency promotes early T cell precursor-like leukemia in NrasQ61R/+ mice. Leukemia, 2022, , .	3.3	0
694	Drug targeting opportunities en route to Ras nanoclusters. Advances in Cancer Research, 2022, 153, 63-99.	1.9	5
695	Q61 mutant-mediated dynamics changes of the GTP-KRAS complex probed by Gaussian accelerated molecular dynamics and free energy landscapes. RSC Advances, 2022, 12, 1742-1757.	1.7	20
696	KRAS and MET in non-small-cell lung cancer: two of the new kids on the â€˜driversâ€™ block. Therapeutic Advances in Respiratory Disease, 2022, 16, 175346662110660.	1.0	6
697	Classical RAS proteins are not essential for paradoxical ERK activation induced by RAF inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	8
698	The path to the clinic: a comprehensive review on direct KRASG12C inhibitors. Journal of Experimental and Clinical Cancer Research, 2022, 41, 27.	3.5	73
700	BAP1 Downregulates NRF2 Target Genes and Exerts Anti-Tumorigenic Effects by Deubiquitinating KEAP1 in Lung Adenocarcinoma. Antioxidants, 2022, 11, 114.	2.2	3
701	The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer. Scientific Reports, 2022, 12, 293.	1.6	6
703	Strategies for designing proteolysis targeting chimaeras (PROTACs). Medicinal Research Reviews, 2022, 42, 1280-1342.	5.0	48
704	Precision medicine for metastatic colorectal cancer in clinical practice. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110727.	1.4	23
705	Targeting KRAS mutant lung cancer: light at the end of the tunnel. Molecular Oncology, 2022, 16, 1057-1071.	2.1	23
706	Current developments in extracellular-regulated protein kinase (ERK1/2) inhibitors. Drug Discovery Today, 2022, , .	3.2	5
707	Radio Signals from Live Cells: The Coming of Age of In-Cell Solution NMR. Chemical Reviews, 2022, 122, 9267-9306.	23.0	42
708	Not all RAS mutations are equal: A detailed review of the functional diversity of RAS hot spot mutations. Advances in Cancer Research, 2022, 153, 29-61.	1.9	14
709	Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone. Advances in Cancer Research, 2022, 153, 131-168.	1.9	4
710	Ras Multimers on the Membrane: Many Ways for a Heart-to-Heart Conversation. Genes, 2022, 13, 219.	1.0	7
711	A Structure is Worth a Thousand Words: New Insights for RAS and RAF Regulation. Cancer Discovery, 2022, 12, 899-912.	7.7	23
712	R-Ras1 and R-Ras2 Expression in Anatomical Regions and Cell Types of the Central Nervous System. International Journal of Molecular Sciences, 2022, 23, 978.	1.8	1

#	Article	IF	Citations
713	Targeting RAS oncogenesis with SOS1 inhibitors. Advances in Cancer Research, 2022, 153, 169-203.	1.9	13
714	Defining RASopathy. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	26
715	Targeting KRAS G12C mutation in lung adenocarcinoma. Lung Cancer, 2022, 165, 28-33.	0.9	10
716	The GSK3 kinase and LZTR1 protein regulate the stability of Ras family proteins and the proliferation of pancreatic cancer cells. Neoplasia, 2022, 25, 28-40.	2.3	6
717	Predicting the conformational variability of oncogenic GTP-bound G12D mutated KRas-4B proteins at zwitterionic model cell membranes. Nanoscale, 2022, 14, 3148-3158.	2.8	10
718	Design, synthesis and bioactivity evaluation of novel quinazoline based KRAS^{G12C} inhibitors. New Journal of Chemistry, 2022, 46, 4827-4836.	1.4	2
720	Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduction and Targeted Therapy, 2022, 7, 39.	7.1	158
721	RAS Mutation Conversion in Bevacizumab-Treated Metastatic Colorectal Cancer Patients: A Liquid Biopsy Based Study. Cancers, 2022, 14, 802.	1.7	8
722	Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants. Cell Reports, 2022, 38, 110322.	2.9	11
723	Carotenoids from Marine Sources as a New Approach in Neuroplasticity Enhancement. International Journal of Molecular Sciences, 2022, 23, 1990.	1.8	4
724	Absorption, Distribution, Metabolism, and Excretion of [¹⁴C]-Sotorasib in Rats and Dogs: Interspecies Differences in Absorption, Protein Conjugation and Metabolism. Drug Metabolism and Disposition, 2022, 50, 600-612.	1.7	5
725	Targeting KRAS in NSCLC: Old Failures and New Options for â€œNon-G12câ€•Patients. Cancers, 2021, 13, 6332.	1.7	10
726	Anticancer drug resistance: An update and perspective. Drug Resistance Updates, 2021, 59, 100796.	6.5	122
727	Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS^{G12D} Inhibitor. Journal of Medicinal Chemistry, 2022, 65, 3123-3133.	2.9	243
728	Signaling Pathways that Regulate Macropinocytosis in Mammalian Cells. Sub-Cellular Biochemistry, 2022, 98, 143-167.	1.0	5
729	Understanding the influence of AMG 510 on the structure of KRASG12C empowered by molecular dynamics simulation. Computational and Structural Biotechnology Journal, 2022, 20, 1056-1067.	1.9	5
730	LncRNA Biomarkers of Inflammation and Cancer. Advances in Experimental Medicine and Biology, 2022, 1363, 121-145.	0.8	15
731	Chirurgische Onkologie. , 2022, , 369-381.		0

#	Article	IF	Citations
732	Biology and pathophysiology of central nervous system metastases. , 2022, , 55-78.		0
734	Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies. Frontiers in Oncology, 2022, 12, 796832.	1.3	34
735	Enhanced O-GlcNAc modification induced by the RAS/MAPK/CDK1 pathway is required for SOX2 protein expression and generation of cancer stem cells. Scientific Reports, 2022, 12, 2910.	1.6	9
736	Breadth and Specificity in Pleiotropic Protein Kinase A Activity and Environmental Responses. Frontiers in Cell and Developmental Biology, 2022, 10, 803392.	1.8	3
737	Zinc ions negatively regulate proapoptotic signaling in cells expressing oncogenic mutant Ras. BioMetals, 2022, 35, 349-362.	1.8	1
738	An Assessment of the Therapeutic Landscape for the Treatment of Heart Disease in the RASopathies. Cardiovascular Drugs and Therapy, 2022, , 1.	1.3	3
739	First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS^{G12C} Solid Tumors (KRYSTAL-1). Journal of Clinical Oncology, 2022, 40, 2530-2538.	0.8	130
740	Inhibiting mutant KRAS G12D gene expression using novel peptide nucleic acidâ€based antisense: A potential new drug candidate for pancreatic cancer. Oncology Letters, 2022, 23, 130.	0.8	6
741	Insights into the Cross Talk between Effector and Allosteric Lobes of KRAS from Methyl Conformational Dynamics. Journal of the American Chemical Society, 2022, 144, 4196-4205.	6.6	14
742	TSPAN6 is a suppressor of Ras-driven cancer. Oncogene, 2022, 41, 2095-2105.	2.6	4
744	Understanding and drugging RAS: 40â€…years to break the tip of the iceberg. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	1
745	Selumetinib: a selective MEK1 inhibitor for solid tumor treatment. Clinical and Experimental Medicine, 2023, 23, 229-244.	1.9	10
746	A Novel Ras–Related Signature Improves Prognostic Capacity in Oesophageal Squamous Cell Carcinoma. Frontiers in Genetics, 2022, 13, 822966.	1.1	3
747	A hotspot mutation targeting the R-RAS2 GTPase acts as a potent oncogenic driver in a wide spectrum of tumors. Cell Reports, 2022, 38, 110522.	2.9	7
748	An In Vivo Inflammatory Loop Potentiates KRAS Blockade. Biomedicines, 2022, 10, 592.	1.4	4
749	RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia. Leukemia, 2022, 36, 1237-1252.	3.3	12
750	The Influence of Oncogenic RAS on Chemotherapy and Radiotherapy Resistance Through DNA Repair Pathways. Frontiers in Cell and Developmental Biology, 2022, 10, 751367.	1.8	12
751	Regulation of GTPase function by autophosphorylation. Molecular Cell, 2022, 82, 950-968.e14.	4.5	9

#	Article	IF	Citations
752	P2RY14 cAMP signaling regulates Schwann cell precursor self-renewal, proliferation, and nerve tumor initiation in a mouse model of neurofibromatosis. ELife, 2022, 11, .	2.8	5
753	Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies. International Journal of Molecular Sciences, 2022, 23, 3706.	1.8	5
754	Iron out KRAS-driven cancer. Journal of Experimental Medicine, 2022, 219, .	4.2	2
755	SGSM2 inhibits thyroid cancer progression by activating RAP1 and enhancing competitive RAS inhibition. Cell Death and Disease, 2022, 13, 218.	2.7	4
756	Establishment and characterization of an immortalized human giant congenital melanocytic nevi cell line. Pigment Cell and Melanoma Research, 2022, 35, 356-368.	1.5	1
757	Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia. Cancers, 2022, 14, 1335.	1.7	5
758	Pharmacological Effects and Molecular Protective Mechanisms of Astragalus Polysaccharides on Nonalcoholic Fatty Liver Disease. Frontiers in Pharmacology, 2022, 13, 854674.	1.6	12
760	Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways. Toxicology and Applied Pharmacology, 2022, 441, 115988.	1.3	7
761	Autopromotion of K-Ras4B Feedback Activation Through an SOS-Mediated Long-Range Allosteric Effect. Frontiers in Molecular Biosciences, 2022, 9, 860962.	1.6	10
762	Structural basis of activation of the tumor suppressor protein neurofibromin. Molecular Cell, 2022, 82, 1288-1296.e5.	4.5	14
763	Blockade of PD-L1/PD-1 signaling promotes osteo-/odontogenic differentiation through Ras activation. International Journal of Oral Science, 2022, 14, 18.	3.6	3
764	Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report. Frontiers in Oncology, 2022, 12, 863639.	1.3	2
765	The gRASs Is Greener: Potential New Therapies in Lung Cancer with Acquired Resistance to KRASG12C Inhibitors. Cancer Discovery, 2021, 11, 1874-1876.	7.7	5
766	Targeting Mutated KRAS Genes to Treat Solid Tumours. Molecular Diagnosis and Therapy, 2022, 26, 39-49.	1.6	13
767	What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?. Frontiers in Immunology, 2021, 12, 773168.	2.2	18
768	Untangling the KRAS mutated lung cancer subsets and its therapeutic implications. Molecular Biomedicine, 2021, 2, 40.	1.7	3
769	Anlotinib Suppresses Oral Squamous Cell Carcinoma Growth and Metastasis by Targeting the RAS Protein to Inhibit the PI3K/Akt Signalling Pathway. Analytical Cellular Pathology, 2021, 2021, 1-9.	0.7	8
771	Integrating Network Pharmacology and Molecular Docking to Analyse the Potential Mechanism of action of Macleaya cordata (Willd.) R. Br. in the Treatment of Bovine Hoof Disease. Veterinary Sciences, 2022, 9, 11.	0.6	5

#	Article	IF	Citations
772	RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging. Molecular Imaging and Biology, 2022, 24, 498-509.	1.3	4
773	Targeted Long-Read Sequencing Decodes the Transcriptional Atlas of the Founding RAS Gene Family Members. International Journal of Molecular Sciences, 2021, 22, 13298.	1.8	2
774	Liver regeneration biology: Implications for liver tumour therapies. World Journal of Clinical Oncology, 2021, 12, 1101-1156.	0.9	5
775	Novel Small Molecules Capable of Blocking mtRAS-Signaling Pathway. Frontiers in Oncology, 2021, 11, 768022.	1.3	0
776	A network-based matrix factorization framework for ceRNA co-modules recognition of cancer genomic data. Briefings in Bioinformatics, 2022, 23, .	3.2	6
777	Pan-KRAS inhibitors suppress proliferation through feedback regulation in pancreatic ductal adenocarcinoma. Acta Pharmacologica Sinica, 2022, 43, 2696-2708.	2.8	6
778	Comprehensive mutation profile in acute myeloid leukemia patients with RUNX1- RUNX1T1 or CBFB-MYH11 fusions. Turkish Journal of Haematology, 2022, , .	0.2	1
779	Sulfated alginate oligosaccharide exerts antitumor activity and autophagy induction by inactivating MEK1/ERK/mTOR signaling in a KSR1-dependent manner in osteosarcoma. Oncogenesis, 2022, 11, 16.	2.1	10
781	Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2022, 28, 3318-3328.	3.2	45
782	Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. Cancer Discovery, 2022, 12, 1500-1517.	7.7	49
792	Millisecond molecular dynamics simulations of KRas-dimer formation and interfaces. Biophysical Journal, 2022, 121, 3730-3744.	0.2	6
794	Cross-species analysis of LZTR1 loss-of-function mutants demonstrates dependency to RIT1 orthologs. ELife, 2022, 11, .	2.8	8
795	Clinical management of metastatic colorectal cancer in the era of precision medicine. Ca-A Cancer Journal for Clinicians, 2022, 72, 372-401.	157.7	167
796	Polyamines in cancer: integrating organismal metabolism and antitumour immunity. Nature Reviews Cancer, 2022, 22, 467-480.	12.8	89
797	Molecular Pathways and Mechanisms of BRAF in Cancer Therapy. Clinical Cancer Research, 2022, 28, 4618-4628.	3.2	37
798	Evidence for reduced BRCA2 functional activity in Homo sapiens after divergence from the chimpanzee-human last common ancestor. Cell Reports, 2022, 39, 110771.	2.9	5
799	Inside the cracked kernel: establishing the molecular basis of AMG510 and MRTX849 in destabilising KRASG12C mutant switch I and II in cancer treatment. Journal of Biomolecular Structure and Dynamics, 2022, , 1-13.	2.0	4
800	Virtual Screening Based on Machine Learning Explores Mangrove Natural Products as KRASG12C Inhibitors. Pharmaceuticals, 2022, 15, 584.	1.7	4

#	Article	IF	Citations
801	Mutation of PTPN11 (Encoding SHP-2) Promotes MEK Activation and Malignant Progression in Neurofibromin-Deficient Cells in a Manner Sensitive to BRAP Mutation. Cancers, 2022, 14, 2377.	1.7	1
802	RHOA takes the RHOad less traveled to cancer. Trends in Cancer, 2022, 8, 655-669.	3.8	11
803	Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12Câ€“Mutant Cancers. Cancer Research Communications, 2022, 2, 342-352.	0.7	12
804	Worldwide Prevalence and Clinical Characteristics of RAS Mutations in Head and Neck Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2022, 12, .	1.3	5
805	Differential expression analysis of genes and long non-coding RNAs associated with KRAS mutation in colorectal cancer cells. Scientific Reports, 2022, 12, 7965.	1.6	8
806	The mechanism of activation of MEK1 by B-Raf and KSR1. Cellular and Molecular Life Sciences, 2022, 79, 281.	2.4	7
807	Ferroptosis and cancer immunotherapy. Current Molecular Medicine, 2022, 22, .	0.6	4
808	Free Energy Profiles Relating With Conformational Transition of the Switch Domains Induced by G12 Mutations in GTP-Bound KRAS. Frontiers in Molecular Biosciences, 2022, 9, 912518.	1.6	15
809	Delineating the RAS Conformational Landscape. Cancer Research, 2022, 82, 2485-2498.	0.4	10
810	Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development. Cancer Letters, 2022, 539, 215716.	3.2	8
811	More to the RAS Story: KRAS^{G12C} Inhibition, Resistance Mechanisms, and Moving Beyond KRAS^{G12C}. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 205-217.	1.8	13
812	Penipentenone A and brefeldin A derivatives potently inhibit KRAS mutant cancer cells from an endophytic fungus Penicillium brefeldianum F4a. Phytochemistry, 2022, 200, 113243.	1.4	4
813	The role of endothelin and RAS/ERK signaling in immunopathogenesis-related fibrosis in patients with systemic sclerosis: an updated review with therapeutic implications. Arthritis Research and Therapy, 2022, 24, 108.	1.6	8
814	Role of miRNAs in Human T Cell Leukemia Virus Type 1 Induced T Cell Leukemia: A Literature Review and Bioinformatics Approach. International Journal of Molecular Sciences, 2022, 23, 5486.	1.8	5
815	Human endogenous retroviruses and hematological malignant tumors. Infectious Microbes & Diseases, 0, Publish Ahead of Print, .	0.5	0
816	Development of a potent smallâ€molecule degrader against oncogenic <scp>BRAF^{V600E}</scp> protein that evades paradoxical <scp>MAPK</scp> activation. Cancer Science, 2022, 113, 2828-2838.	1.7	5
817	Src kinase: An attractive therapeutic target for prostate cancer. , 2022, , 479-503.		0
819	Targeting RASâ€“RAFâ€“MEKâ€“ERK signaling pathway in human cancer: Current status in clinical trials. Genes and Diseases, 2023, 10, 76-88.	1.5	34

#	Article	IF	Citations
820	ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. Molecular Cell, 2022, 82, 2443-2457.e7.	4.5	9
822	HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature. Current Oncology, 2022, 29, 3748-3758.	0.9	7
823	Non-melanoma skin cancers: physio-pathology and role of lipid delivery systems in new chemotherapeutic treatments. Neoplasia, 2022, 30, 100810.	2.3	10
825	The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old targetâ€"a narrative review. Translational Lung Cancer Research, 2021, .	1.3	4
827	NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease. International Journal of Molecular Sciences, 2022, 23, 6748.	1.8	12
828	Semaphorin-3 Promotes Specific Immunotherapy Effects on Experimental Food Allergy. Journal of Immunology Research, 2022, 2022, 1-15.	0.9	2
829	Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation. Nature Communications, 2022, 13, .	5.8	11
830	G-Protein Phosphorylation: Aspects of Binding Specificity and Function in the Plant Kingdom. International Journal of Molecular Sciences, 2022, 23, 6544.	1.8	6
831	RASAL2 regulates the cell cycle and cyclin D1 expression through PI3K/AKT signalling in prostate tumorigenesis. Cell Death Discovery, 2022, 8, .	2.0	6
832	RAF1 promotes lymphatic metastasis of hypopharyngeal carcinoma via regulating LAGE1: an experimental research. Journal of Translational Medicine, 2022, 20, .	1.8	10
833	PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	77
834	Targeting molecular alterations in non-small-cell lung cancer: what's next?. Personalized Medicine, 0, , .	0.8	4
835	Accelerated Identification of Cell Active KRAS Inhibitory Macrocyclic Peptides using Mixture Libraries and Automated Ligand Identification System (ALIS) Technology. Journal of Medicinal Chemistry, 2022, 65, 8961-8974.	2.9	7
836	Prolactin: The Third Hormone in Breast Cancer. Frontiers in Endocrinology, 0, 13, .	1.5	15
837	The Role of Serial Liquid Biopsy in the Management of Metastatic Non-Small Cell Lung Cancer (NSCLC). Clinics and Practice, 2022, 12, 419-424.	0.6	4
838	Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells. Molecular Cancer, 2022, 21, .	7.9	21
839	Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	14
840	Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer. Cancer Treatment Reviews, 2022, 109, 102433.	3.4	15

#	Article	IF	Citations
841	Crucial Role of Oncogenic KRAS Mutations in Apoptosis and Autophagy Regulation: Therapeutic Implications. Cells, 2022, 11, 2183.	1.8	18
842	A 2-tier subdivision of papillary proliferations of the endometrium (PPE) only emphasizing the complexity of papillae precisely predicts the neoplastic risk and reflects the neoplasia-related molecular characteristicsâ€"a single-centered analysis of 207 cases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 585-593.	1.4	1
843	Structure of the MRASâ€"SHOC2â€"PP1C phosphatase complex. Nature, 2022, 609, 416-423.	13.7	11
844	Structureâ€"function analysis of the SHOC2â€"MRASâ€"PP1C holophosphatase complex. Nature, 2022, 609, 408-415.	13.7	28
845	Colorectal cancer-derived exosomes and modulation KRAS signaling. Clinical and Translational Oncology, 2022, 24, 2074-2080.	1.2	2
846	Genetics of brain arteriovenous malformations and cerebral cavernous malformations. Journal of Human Genetics, 2023, 68, 157-167.	1.1	3
847	Skin cancer and DNA mutation due to ultraviolet radiation. International Journal of Research in Dermatology, 2022, 8, 508.	0.0	1
848	Precision Anti-Cancer Medicines by Oligonucleotide Therapeutics in Clinical Research Targeting Undruggable Proteins and Non-Coding RNAs. Pharmaceutics, 2022, 14, 1453.	2.0	6
850	Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Proteinâ€"Protein Interaction. Journal of Medicinal Chemistry, 2022, 65, 9678-9690.	2.9	29
851	Cancer Biology and Implications for the Perioperative Period. , 2023, , 24-45.		1
852	Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S). Nature Chemical Biology, 2022, 18, 1177-1183.	3.9	49
853	Mutant KRAS regulates transposable element RNA and innate immunity via KRAB zinc-finger genes. Cell Reports, 2022, 40, 111104.	2.9	7
854	Lipid-related FABP5 activation of tumor-associated monocytes fosters immune privilege via PD-L1 expression on Treg cells in hepatocellular carcinoma. Cancer Gene Therapy, 2022, 29, 1951-1960.	2.2	17
855	Ras-mutant cancers are sensitive to small molecule inhibition of V-type ATPases in mice. Nature Biotechnology, 2022, 40, 1834-1844.	9.4	13
856	Therapeutic Outcomes and Clinical Features of Advanced Non-small Cell Lung Cancer carrying KRAS Mutations: a Multicenter Real-Life Retrospective Study. Clinical Lung Cancer, 2022, , .	1.1	0
857	Nanoscopic Spatial Association between Ras and Phosphatidylserine on the Cell Membrane Studied with Multicolor Super Resolution Microscopy. Biomolecules, 2022, 12, 1033.	1.8	6
858	Boosting Antitumor Immunity with an Expanded Neoepitope Landscape. Cancer Research, 2022, 82, 3637-3649.	0.4	4
859	Argonaute 2 modulates EGFRâ€"RAS signaling to promote mutant HRAS and NRAS-driven malignancies. , 2022, 1, .		1

#	Article	IF	Citations
860	Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRASG12C. Frontiers in Oncology, 0, 12, .	1.3	5
861	Oncohistones: Exposing the nuances and vulnerabilities of epigenetic regulation. Molecular Cell, 2022, 82, 2925-2938.	4.5	20
862	Cutaneous manifestations in Costello syndrome: HRAS p.Gly12Ser affects RIN1-mediated integrin trafficking in immortalized epidermal keratinocytes. Human Molecular Genetics, 2023, 32, 304-318.	1.4	2
863	Immune-based combination therapy to convert immunologically cold tumors into hotÂtumors: an update and new insights. Acta Pharmacologica Sinica, 2023, 44, 288-307.	2.8	14
864	Structural keys unlock RASâ€“MAPK cellular signalling pathway. Nature, 0, , .	13.7	3
865	Chemoselective Covalent Modification of K-Ras(G12R) with a Small Molecule Electrophile. Journal of the American Chemical Society, 2022, 144, 15916-15921.	6.6	45
867	KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges. International Journal of Molecular Sciences, 2022, 23, 9391.	1.8	13
868	TGFÎ²-induced changes in membrane curvature influence Ras oncoprotein membrane localization. Scientific Reports, 2022, 12, .	1.6	4
869	Identification and validation of four photodynamic therapy related genes inhibiting MAPK and inducing cell cycle alteration in squamous cell carcinoma. Frontiers in Oncology, 0, 12, .	1.3	0
870	A biology-informed similarity metric for simulated patches of human cell membrane. Machine Learning: Science and Technology, 2022, 3, 035010.	2.4	1
871	Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Molecular Cancer, 2022, 21, .	7.9	55
872	Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers. Cancers, 2022, 14, 4103.	1.7	14
873	Palmitoylation of GNAQ/11 is critical for tumor cell proliferation and survival in GNAQ/11-mutant uveal melanoma. Frontiers of Medicine, 2022, 16, 784-798.	1.5	2
874	Temporally restricted activation of IFNÎ² signaling underlies response to immune checkpoint therapy in mice. Nature Communications, 2022, 13, .	5.8	12
875	Targeting protein conformations with small molecules to control protein complexes. Trends in Biochemical Sciences, 2022, 47, 1023-1037.	3.7	3
876	The current state of the art and future trends in RAS-targeted cancer therapies. Nature Reviews Clinical Oncology, 2022, 19, 637-655.	12.5	125
877	A Novel Defined RAS-Related Gene Signature for Predicting the Prognosis and Characterization of Biological Function in Osteosarcoma. Journal of Oncology, 2022, 2022, 1-15.	0.6	1
878	RASopathies due to de novo pathogenic variants: clinical features, genetic findings and outcomes in nine neonates born with congenital heart defects. BMC Medical Genomics, 2022, 15, .	0.7	1

#	Article	IF	Citations
879	Synthesis, biological evaluation, and bindingâ€mode of a new class of oncogenic Kâ€Ras4B inhibitors. ChemMedChem, 0, , .	1.6	2
880	Mechanistic Insights into the Long-range Allosteric Regulation of KRAS Via Neurofibromatosis Type 1 (NF1) Scaffold Upon SPRED1 Loading. Journal of Molecular Biology, 2022, 434, 167730.	2.0	17
881	Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents. Bioorganic and Medicinal Chemistry, 2022, 71, 116962.	1.4	6
882	Discovery and biological evaluation of 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one derivatives as covalent inhibitors of KRAS G12C with favorable metabolic stability and anti-tumor activity. Bioorganic and Medicinal Chemistry, 2022, 71, 116949.	1.4	6
883	Development of fluorizoline analogues as prohibitin ligands that modulate C-RAF signaling, p21 expression and melanogenesis. European Journal of Medicinal Chemistry, 2022, 242, 114635.	2.6	1
884	Mitochondrial fragmentation in liver cancer: Emerging player and promising therapeutic opportunities. Cancer Letters, 2022, 549, 215912.	3.2	7
885	Targeting GRP78 suppresses oncogenic KRAS protein expression and reduces viability of cancer cells bearing various KRAS mutations. Neoplasia, 2022, 33, 100837.	2.3	9
886	XBP1 is required in Th2 polarization induction in airway allergy. Theranostics, 2022, 12, 5337-5349.	4.6	4
887	Therapeutic peptidomimetics for cancer treatment. , 2022, , 473-505.		0
888	Conquering oncogenic KRAS and its bypass mechanisms. Theranostics, 2022, 12, 5691-5709.	4.6	1
889	KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer. Journal of Cancer, 2022, 13, 3209-3220.	1.2	10
890	Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211180.	1.4	13
891	Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer. Science Translational Medicine, 2022, 14, .	5.8	12
893	Immune dysregulation associated with co-occurring germline CBL and SH2B3 variants. Human Genomics, 2022, 16, .	1.4	2
894	PHLDA1 promotes glioblastoma cell growth via sustaining the activation state of Ras. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	3
895	Effect of TP53 deficiency and KRAS signaling on the bioenergetics of colon cancer cells in response to different substrates: A single cell study. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	2
896	KRAS protein expression becomes progressively restricted during embryogenesis and in adulthood. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	1
898	Controlled Rehydration of Dried Reagents for Robust Multiplex Digital PCR. Analytical Chemistry, 2022, 94, 13223-13232.	3.2	2

#	Article	IF	Citations
899	Fluorescent Biosensor for Measuring Ras Activity in Living Cells. Journal of the American Chemical Society, 2022, 144, 17432-17440.	6.6	6
900	Genetics, molecular control and clinical relevance of habituation learning. Neuroscience and Biobehavioral Reviews, 2022, 143, 104883.	2.9	3
901	Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers. Cancer Research, 2022, 82, 4058-4078.	0.4	4
902	Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis. ELife, 0, 11, .	2.8	4
903	Computer-Aided Drug Design Boosts RAS Inhibitor Discovery. Molecules, 2022, 27, 5710.	1.7	6
904	Structure of the SHOC2â€“MRASâ€“PP1C complex provides insights into RAF activation and Noonan syndrome. Nature Structural and Molecular Biology, 2022, 29, 966-977.	3.6	10
905	Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis. , 2022, 19, 1153-1167.		6
906	MAPK Signaling Pathway in Oral Squamous Cell Carcinoma: Biological Function and Targeted Therapy. Cancers, 2022, 14, 4625.	1.7	13
907	Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo. Cell Communication and Signaling, 2022, 20, .	2.7	8
909	Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines. Cancers, 2022, 14, 4467.	1.7	6
910	Combinatorial approaches for mitigating resistance to KRAS-targeted therapies. Biochemical Journal, 2022, 479, 1985-1997.	1.7	2
912	Targeting Extracellular Signal-Regulated Protein Kinase 1/2 (ERK1/2) in Cancer: An Update on Pharmacological Small-Molecule Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 13561-13573.	2.9	12
913	Research progress in the establishment of pancreatic cancer models and preclinical applications. , 2022, 1, 207-219.		0
914	Oncogenic role of a developmentally regulated NTRK2 splice variant. Science Advances, 2022, 8, .	4.7	1
916	Design, synthesis, and evaluation of 4(1H)-quinolinone and urea derivatives as KRASG12C inhibitors with potent antitumor activity against KRAS-mutant non-small cell lung cancer. European Journal of Medicinal Chemistry, 2022, 244, 114808.	2.6	2
917	Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis. International Urology and Nephrology, 2023, 55, 1025-1032.	0.6	3
918	Bioconjugation Strategies for Revealing the Roles of Lipids in Living Cells. Accounts of Chemical Research, 2022, 55, 3099-3109.	7.6	7
919	AMPylation of small GTPases by Fic enzymes. FEBS Letters, 2023, 597, 883-891.	1.3	2

#	Article	IF	Citations
920	Effects of Noonan Syndrome-Germline Mutations on Mitochondria and Energy Metabolism. Cells, 2022, 11, 3099.	1.8	5
921	Ras inhibitors gate chemoattractant concentration range for chemotaxis through controlling GPCR-mediated adaptation and cell sensitivity. Frontiers in Immunology, 0, 13, .	2.2	1
922	Î²-Carboline dimers inhibit the tumor proliferation by the cell cycle arrest of sarcoma through intercalating to Cyclin-A2. Frontiers in Immunology, 0, 13, .	2.2	2
924	RAS oncogene signal strength regulates matrisomal gene expression and tumorigenicity of mouse keratinocytes. Carcinogenesis, 0, , .	1.3	0
925	Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	54
926	Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective. Cancers, 2022, 14, 4828.	1.7	11
927	Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	8
928	Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS^{G12C} Inhibitor. Journal of Medicinal Chemistry, 2022, 65, 14614-14629.	2.9	19
929	A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers. Cell Research, 2023, 33, 30-45.	5.7	14
930	Process Research for ZG1077, a KRAS G12C Inhibitor. Organic Process Research and Development, 2022, 26, 2986-2996.	1.3	0
931	Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRASG12D inhibitors for cancer therapy. Scientific Reports, 2022, 12, .	1.6	24
932	Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer. Molecular Cancer Therapeutics, 2023, 22, 135-149.	1.9	2
933	Precision oncology provides opportunities for targeting KRAS-inhibitor resistance. Trends in Cancer, 2023, 9, 42-54.	3.8	13
934	Licoricidin combats gastric cancer by targeting the ICMT/Ras pathway in vitro and in vivo. Frontiers in Pharmacology, 0, 13, .	1.6	6
935	The Next Generation of KRAS Targeting: Reasons for Excitement and Concern. Molecular Cancer Therapeutics, 2022, 21, 1645-1651.	1.9	6
936	Options of Therapeutics and Novel Delivery Systems of Drugs for the Treatment of Melanoma. Molecular Pharmaceutics, 2022, 19, 4487-4505.	2.3	11
937	Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nature Medicine, 2022, 28, 2171-2182.	15.2	131
938	Pharmacophoric analogs of sotorasib-entrapped KRAS G12C in its inactive GDP-bound conformation: covalent docking and molecular dynamics investigations. Molecular Diversity, 2023, 27, 1795-1807.	2.1	3

#	Article	IF	Citations
939	G3BP2: Structure and function. Pharmacological Research, 2022, 186, 106548.	3.1	6
940	The role of KRAS splice variants in cancer biology. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	16
941	Enhancing an Oxidative â€œTrojan Horseâ€•Action of Vitamin C with Arsenic Trioxide for Effective Suppression of KRAS-Mutant Cancers: A Promising Path at the Bedside. Cells, 2022, 11, 3454.	1.8	2
942	Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors. European Journal of Cancer, 2022, 177, 120-142.	1.3	8
943	The dynamicity of mutant KRAS Î²2 strand modulates its downstream activation and predicts anticancer KRAS inhibition. Life Sciences, 2022, 310, 121053.	2.0	0
944	Prostaglandin E2 in neuroblastoma: Targeting synthesis or signaling?. Biomedicine and Pharmacotherapy, 2022, 156, 113966.	2.5	6
945	Identification of novel Pyrrolo[2,3-d]Pyrimidine-based KRAS G12C inhibitors with anticancer effects. European Journal of Medicinal Chemistry, 2023, 245, 114907.	2.6	6
947	Whole exome sequencing based identification of a case of cardiofaciocutaneous syndrome type 3: the benefits of new sequencing technology in children with neurodevelopmental delay. BMJ Case Reports, 2022, 15, e251871.	0.2	0
948	Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun. Current Treatment Options in Oncology, 2022, 23, 1699-1720.	1.3	5
949	Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening. Current Oncology, 2022, 29, 8693-8719.	0.9	5
950	The molecular genetics of <scp>RASopathies</scp>: An update on novel disease genes and new disorders. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2022, 190, 425-439.	0.7	11
951	Molecular docking analysis reveals differential binding affinities of multiple classes of selective inhibitors towards cancer-associated KRAS mutants. 3 Biotech, 2022, 12, .	1.1	1
952	Mutations in the Î±4-Î±5 allosteric lobe of RAS do not significantly impair RAS signaling or self-association. Journal of Biological Chemistry, 2022, 298, 102661.	1.6	2
953	A Prognostic Risk Model of a Novel Oxidative Stress-Related Signature Predicts Clinical Prognosis and Demonstrates Immune Relevancy in Lung Adenocarcinoma. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-43.	1.9	2
954	JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS^{G12C} for the Treatment of Solid Tumors. Journal of Medicinal Chemistry, 2022, 65, 16173-16203.	2.9	31
955	The era of high-quality chemical probes. RSC Medicinal Chemistry, 2022, 13, 1446-1459.	1.7	15
956	Structural basis of the oncogenic KRAS mutant and GJ101 complex. Biochemical and Biophysical Research Communications, 2023, 641, 27-33.	1.0	2
957	Site-Specific Activity-Based Protein Profiling Using Phosphonate Handles. Molecular and Cellular Proteomics, 2023, 22, 100455.	2.5	3

#	Article	IF	Citations
958	Binding of active Ras and its mutants to the Ras binding domain of PI-3-kinase: A quantitative approach to KD measurements. Analytical Biochemistry, 2023, 663, 115019.	1.1	1
960	Novel 1,4-dihydropyrido[2,3-b]pyrazine-2,3-dione derivatives for treating cancer and other disorders associated with KRAS activity. Anti-Cancer Agents in Medicinal Chemistry, 2022, 23, .	0.9	0
961	Brain AVMs-Related microRNAs: Machine Learning Algorithm for Expression Profiles of Target Genes. Brain Sciences, 2022, 12, 1628.	1.1	2
962	Silencing effects of mutant RAS signalling on transcriptomes. Advances in Biological Regulation, 2022, , 100936.	1.4	0
963	CD229 interacts with RASAL3 to activate RAS/ERK pathway in multiple myeloma proliferation. Aging, 2022, 14, 9264-9279.	1.4	1
964	Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47. Journal of Clinical Investigation, 2023, 133, .	3.9	16
965	PROTAC therapy as a new targeted therapy for lung cancer. Molecular Therapy, 2023, 31, 647-656.	3.7	13
966	Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RAS. ELife, 0, 11, .	2.8	4
967	Synthesis, molecular docking, and in-vitro studies of pyrimidine-2-thione derivatives as antineoplastic agents via potential RAS/PI3K/Akt/JNK inhibition in breast carcinoma cells. Scientific Reports, 2022, 12, .	1.6	5
968	KRAS pathway-based therapeutic approaches in pancreatic cancer. Mini-Reviews in Medicinal Chemistry, 2022, 23, .	1.1	0
969	Tumor cells fail to present MHC-IIâ€“restricted epitopes derived from oncogenes to CD4+ T cells. JCI Insight, 2023, 8, .	2.3	6
970	Clinical and Molecular Attributes and Evaluation of Pancreatic Cystic Neoplasm. Biochimica Et Biophysica Acta: Reviews on Cancer, 2023, 1878, 188851.	3.3	2
971	Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAFV600E Protein. Molecules, 2022, 27, 8513.	1.7	4
972	Characterization of mutant versions of the R-RAS2/TC21 GTPase found in tumors. Oncogene, 2023, 42, 389-405.	2.6	1
974	Discovery of potent and noncovalent KRASG12D inhibitors: Structure-based virtual screening and biological evaluation. Frontiers in Pharmacology, 0, 13, .	1.6	3
977	Kinetic and Mechanistic Investigations to Enable a Key Suzuki Coupling for Sotorasib Manufactureâ”€What a Difference a Base Makes. Organic Process Research and Development, 2023, 27, 198-205.	1.3	7
979	Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. Molecular Biomedicine, 2022, 3, .	1.7	8
980	Efficacy of encorafenib and cetuximab therapy in a young patient with a rare concomitant KRAS and BRAF mutation in primary rectal cancer and wild-type KRAS status in metastases: A case report and literature review. Current Problems in Cancer Case Reports, 2022, 8, 100207.	0.1	0

#	Article	IF	Citations
982	Development of a high-throughput TR-FRET screening assay for a fast-cycling KRAS mutant. SLAS Discovery, 2023, 28, 39-47.	1.4	1
983	Melanogenesis and the Targeted Therapy of Melanoma. Biomolecules, 2022, 12, 1874.	1.8	9
985	Dynamic regulation of RAS and RAS signaling. Biochemical Journal, 2023, 480, 1-23.	1.7	16
986	Design, synthesis and biological evaluation of KRASG12C-PROTACs. Bioorganic and Medicinal Chemistry, 2023, 78, 117153.	1.4	7
987	Gene-Function-Based Clusters Explore Intricate Networks of Gene Expression of Circulating Tumor Cells in Patients with Colorectal Cancer. Biomedicines, 2023, 11, 145.	1.4	0
988	Progress of small molecules for targeted protein degradation: PROTACs and other technologies. Drug Development Research, 2023, 84, 337-394.	1.4	6
989	A pyroptosis-related gene signature provides an alternative for predicting the prognosis of patients with hepatocellular carcinoma. BMC Medical Genomics, 2023, 16, .	0.7	1
990	Abnormal expression of H-Ras induces S-phase arrest and mitotic catastrophe in human T-lymphocyte leukemia. Blood Research, 2023, 58, 20-27.	0.5	1
991	BRAF RNA is prognostic and widely expressed in lung adenocarcinoma. Translational Lung Cancer Research, 2023, 12, 27-41.	1.3	2
992	Novel Insights into the Role of Kras in Myeloid Differentiation: Engaging with Wnt/Î²-Catenin Signaling. Cells, 2023, 12, 322.	1.8	0
993	Annual review of KRAS inhibitors in 2022. European Journal of Medicinal Chemistry, 2023, 249, 115124.	2.6	15
994	Targeting KRAS-mutant stomach/colorectal tumors by disrupting the ERK2-p53 complex. Cell Reports, 2023, 42, 111972.	2.9	2
995	The Double-Edged Proteins in Cancer Proteomes and the Generation of Induced Tumor-Suppressing Cells (iTSCs). Proteomes, 2023, 11, 5.	1.7	2
996	Î±4-Î±5 Helices on Surface of KRAS Can Accommodate Small Compounds That Increase KRAS Signaling While Inducing CRC Cell Death. International Journal of Molecular Sciences, 2023, 24, 748.	1.8	2
997	Ras superfamily GTPase activating proteins in cancer: Potential therapeutic targets?. European Journal of Medicinal Chemistry, 2023, 248, 115104.	2.6	3
998	An explainable AI-driven biomarker discovery framework for Non-Small Cell Lung Cancer classification. Computers in Biology and Medicine, 2023, 153, 106544.	3.9	10
999	Stress granules dynamics: benefits in cancer. BMB Reports, 2022, 55, 577-586.	1.1	9
1000	As a novel anticancer candidate, ether extract of Dendrobium nobile overstimulates cellular protein biosynthesis to induce cell stress and autophagy. Journal of Applied Biomedicine, 2023, 21, 23-35.	0.6	3

#	Article	IF	Citations
1001	Hindered Biaryl Bond Construction and Subsequent Diastereomeric Crystallization to Produce an Atropisomeric Covalent KRAS^{G12C} Inhibitor ARS-2102. Organic Process Research and Development, 2023, 27, 206-216.	1.3	3
1002	Eliminating oncogenic RAS: back to the future at the drawing board. Biochemical Society Transactions, 2023, 51, 447-456.	1.6	9
1003	Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers. IScience, 2023, 26, 106082.	1.9	2
1005	The discovery of some promising putative binders of KRAS G12D receptor using computer-aided drug discovery approach. Informatics in Medicine Unlocked, 2023, 37, 101170.	1.9	2
1008	Binding modes of GDP, GTP and GNP to NRAS deciphered by using Gaussian accelerated molecular dynamics simulations. SAR and QSAR in Environmental Research, 2023, 34, 65-89.	1.0	10
1009	Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments. World Journal of Gastroenterology, 0, 29, 926-948.	1.4	4
1010	Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial. Frontiers in Oncology, 0, 13, .	1.3	4
1011	Targeted therapy based on ubiquitin-specific proteases, signalling pathways and E3 ligases in non-small-cell lung cancer. Frontiers in Oncology, 0, 13, .	1.3	1
1013	Alisertib exerts KRAS alleleâ€'specific anticancer effects on colorectal cancer cell lines. Experimental and Therapeutic Medicine, 2023, 25, .	0.8	1
1014	Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma. Biomedicine and Pharmacotherapy, 2023, 161, 114452.	2.5	5
1015	Detection of Ras nanoclustering-dependent homo-FRET using fluorescence anisotropy measurements. European Journal of Cell Biology, 2023, 102, 151314.	1.6	2
1016	KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics. Critical Reviews in Oncology/Hematology, 2023, 186, 103987.	2.0	3
1018	The genetic profile and molecular subtypes of human pseudomyxoma peritonei and appendiceal mucinous neoplasms: a systematic review. Cancer and Metastasis Reviews, 2023, 42, 335-359.	2.7	1
1019	143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models. Acta Pharmacologica Sinica, 0, , .	2.8	0
1020	Cell entry of Bovine herpesvirus-1 through clathrin- and caveolin-mediated endocytosis requires activation of PI3K-Akt-NF-ÎºB and Ras-p38 MAPK pathways as well as the interaction of BoHV-1 gD with cellular receptor nectin-1. Veterinary Microbiology, 2023, 279, 109672.	0.8	3
1021	Dynamic density functional theory of multicomponent cellular membranes. Physical Review Research, 2023, 5, .	1.3	3
1022	Local Hydration Control and Functional Implications Through S-Nitrosylation of Proteins: Kirsten Rat Sarcoma Virus (K-RAS) and Hemoglobin (Hb). Journal of Physical Chemistry B, 2023, 127, 1526-1539.	1.2	2
1023	Classification of GTP-dependent K-Ras4B active and inactive conformational states. Journal of Chemical Physics, 2023, 158, .	1.2	2

#	Article	IF	Citations
1024	Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation. Cell Reports Medicine, 2023, 4, 100940.	3.3	4
1025	Changes of RAS Pathway Phosphorylation in Lymphoblastoid Cell Lines from Noonan Syndrome Patients Carrying Hypomorphic Variants in Two NS Genes. International Journal of Molecular Sciences, 2023, 24, 4035.	1.8	0
1026	The Rise of Gastrointestinal Cancers as a Global Phenomenon: Unhealthy Behavior or Progress?. International Journal of Environmental Research and Public Health, 2023, 20, 3640.	1.2	12
1027	Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical developmentâ€"a narrative review. Translational Lung Cancer Research, 2023, 12, 346-368.	1.3	5
1029	Case report: Revascularization failure in NF1-related moyamoya syndrome after selumetinib: A possible pathophysiological correlation?. Frontiers in Pediatrics, 0, 11, .	0.9	2
1030	Oncogenes. , 2023, , 75-96.		0
1031	KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): Characteristics, treatment patterns and overall survival from a Danish nationwide observational register study. Lung Cancer, 2023, 178, 172-182.	0.9	1
1032	Inhibition mechanism of MRTX1133 on KRASG12D: a molecular dynamics simulation and Markov state model study. Journal of Computer-Aided Molecular Design, 2023, 37, 157-166.	1.3	2
1033	Autophagy and autophagy-related pathways in cancer. Nature Reviews Molecular Cell Biology, 2023, 24, 560-575.	16.1	115
1034	Friend or Foe: Regulation, Downstream Effectors of RRAD in Cancer. Biomolecules, 2023, 13, 477.	1.8	5
1035	Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutantâ€"Novel Insights from Computer-Aided Drug Discovery. Current Issues in Molecular Biology, 2023, 45, 2136-2156.	1.0	5
1036	The Selfâ€Association of the KRAS4b Protein is Altered by Lipidâ€Bilayer Composition and Electrostatics. Angewandte Chemie, 2023, 135, .	1.6	1
1037	The Selfâ€Association of the KRAS4b Protein is Altered by Lipidâ€Bilayer Composition and Electrostatics. Angewandte Chemie - International Edition, 2023, 62, .	7.2	3
1038	Treatment of Recurrent Melanoma Following Adjuvant Therapy. American Journal of Clinical Dermatology, 0, , .	3.3	0
1040	Analysis of context-specific KRASâ€"effector (sub)complexes in Caco-2 cells. Life Science Alliance, 2023, 6, e202201670.	1.3	1
1041	A Comprehensive Review of the Impact of the Renin Angiotensin System in the Liver, Lung, Infectious Diseases and Cancers. , 2023, , 113-131.		0
1042	DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer. Cancer Research, 2023, 83, 1800-1814.	0.4	1
1043	Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib. Journal of Biological Chemistry, 2023, 299, 104634.	1.6	8

#	Article	IF	Citations
1044	KRAS G12C mutation: from black sheep to key player in pancreatic cancer treatment. Future Oncology, 0, , .	1.1	0
1046	Discovery of Clinically Used Octenidine as NRAS Repressor That Effectively Inhibits NRAS-Mutant Melanoma. Journal of Medicinal Chemistry, 2023, 66, 5171-5184.	2.9	5
1047	Impacts of Mutations in the P-Loop on Conformational Alterations of KRAS Investigated with Gaussian Accelerated Molecular Dynamics Simulations. Molecules, 2023, 28, 2886.	1.7	2
1048	Crystal Structure of an iâ€Motif from the HRAS Oncogene Promoter. Angewandte Chemie - International Edition, 2023, 62, .	7.2	5
1049	Crystal Structure of an iâ€Motif from the HRAS Oncogene Promoter. Angewandte Chemie, 2023, 135, .	1.6	0
1050	Phospholipase A and acyltransferase 4/retinoic acid receptor responder 3 at the intersection of tumor suppression and pathogen restriction. Frontiers in Immunology, 0, 14, .	2.2	0
1051	Connecting developmental defects and evolutionary findings. , 2023, , 327-357.		0
1052	Target Hyperactive ERK Signaling for Cancer Therapy. , 2023, , 1-39.		0
1053	Origin and Evolution of RAS Membrane Targeting. Oncogene, 2023, 42, 1741-1750.	2.6	3
1055	Targeting the RhoA-GEF-H1 pathway of mast cells attenuates experimental airway allergy. Archives of Biochemistry and Biophysics, 2023, 741, 109597.	1.4	0
1056	KRAS Pathways: A Potential Gateway for Cancer Therapeutics and Diagnostics. Recent Patents on Anti-Cancer Drug Discovery, 2024, 19, 268-279.	0.8	1
1057	Inhibition of lung adenocarcinoma by combinations of sulfasalazine (SAS) and disulfiram-copper (DSF-Cu) in cell line models and mice. Carcinogenesis, 2023, 44, 291-303.	1.3	2
1058	Setting sail: Maneuvering SHP2 activity and its effects in cancer. Advances in Cancer Research, 2023, , .	1.9	0
1059	Selected Approaches to Disrupting Proteinâ€"Protein Interactions within the MAPK/RAS Pathway. International Journal of Molecular Sciences, 2023, 24, 7373.	1.8	2
1060	Emerging evidence and treatment paradigm of non-small cell lung cancer. Journal of Hematology and Oncology, 2023, 16, .	6.9	17
1062	Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discovery, 2023, 13, 1556-1571.	7.7	31
1063	Structural insights into the role of <scp>SHOC2â€MRASâ€PP1C</scp> complex in <scp>RAF</scp> activation. FEBS Journal, 0, , .	2.2	0
1064	CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code. Lung Cancer: Targets and Therapy, 0, Volume 14, 31-39.	1.3	0

#	Article	IF	Citations
1065	RBM4 dictates ESCC cell fate switch from cellular senescence to glutamine-addiction survival through inhibiting LKB1-AMPK-axis. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	4
1066	Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors. Molecules, 2023, 28, 3615.	1.7	2
1067	MicroRNA-708 emerges as a potential candidate to target undruggable NRAS. PLoS ONE, 2023, 18, e0284744.	1.1	0
1084	Voies en aval des rÃ©cepteurs Ã activitÃ© tyrosine kinase. , 2023, , 35-42.		0
1102	Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	5
1110	Emerging roles of noncoding RNAs in human cancers. Discover Oncology, 2023, 14, .	0.8	1
1122	Proteinâ€“Protein Interactions in Cancer. , 2023, , 43-100.		0
1127	Recent advances in targeting the â€œundruggableâ€•proteins: from drug discovery to clinical trials. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	11
1140	Histology and molecular testing. , 2024, , 69-100.		0
1142	Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma. Targeted Oncology, 2023, 18, 643-655.	1.7	2
1182	Case Report: Case series: association between blood concentration and side effects of sotorasib. Frontiers in Oncology, 0, 13, .	1.3	1
1205	The role of CRAF in cancer progression: from molecular mechanisms to precision therapies. Nature Reviews Cancer, 2024, 24, 105-122.	12.8	3
1215	Precision medicine: success stories and challenges from science to implementation. , 2024, , 83-113.		0
1222	An overview of recent advancements in small molecules suppression of oncogenic signaling of K-RAS: an updated review. Molecular Diversity, 0, , .	2.1	0
1231	Genetically encodable biosensors for Ras activity. RSC Chemical Biology, 2024, 5, 312-320.	2.0	0
1240	Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors. International Review of Cell and Molecular Biology, 2024, , .	1.6	0
1242	Cranial and Paraspinal Nerve Tumors. , 2023, , 231-257.		0
1253	Onkogene. , 2024, , 89-113.		0

#	Article	IF	Citations